GE HealthCare Technologies (GEHC) 10-K risk factor changes: FY2025 vs FY2024

[removed: Any of these] [added: These] risks and other risks could materially and adversely affect our business, results of operations, cash flows, [removed: and] financial [removed: condition] [added: condition, or prospects] and the actual outcome of matters as to which forward-looking statements are made in this Annual Report on Form 10-K.

- Efforts by public and private payers to control the growth of healthcare costs may [removed: lead to lower reimbursements or increased utilization controls related to the use of our products by healthcare providers, which may] affect the price of and demand for our [removed: products, services, or solutions.][added: products and services.]

- Our [removed: increasing focus on and] [added: business strategy includes substantial] investment in [added: R&D, with a focus on AI,] cloud, edge computing, [removed: AI,] and software [removed: offerings present risks to our business.][added: offerings.]

We may not be successful in driving the global deployment and customer adoption of digital [removed: offerings characterized by digital applications] [added: offerings, including cloud-enabled, AI-enabled,] and [removed: solutions.][added: software solutions.]

- Our inability to manage our supply chain or obtain supplies of components or raw materials, as well as any interruption in the operations of our facilities, our suppliers’, customers’, or third-party providers’ facilities, has restricted, and could continue to restrict, the manufacturing of products, cause delays in delivery, impair our ability to deliver products or provide [removed: services] [added: services,] or significantly increase our costs.

[removed: - Increased] [added: Increased] cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted [removed: cyber crimes] [added: cybercrimes] pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, [removed: and we may be unable to obtain, maintain, protect, or effectively enforce our IP rights,] which could adversely affect our [removed: business.][added: business.]

[removed: - If] [added: If] we are unable to attract or retain key [removed: personnel] [added: talent] and qualified employees or maintain relations with our [removed: employees or] [added: employees, unions, and] other employee representatives, it could adversely affect our [removed: business.][added: business.]

- Increasing attention to [removed: ESG] [added: sustainability] matters, including environmental, health, and safety (“EH&S”) matters, may impose additional costs and expose us to new risks.

[removed: - If our] [added: If the] Spin-Off [removed: from GE] is determined to be a taxable transaction, it could result in significant tax liability to GE and its stockholders and we could have an indemnification obligation to GE, which could adversely affect our business, financial condition, cash flows, and results of [removed: operations.][added: operations.]

- We are subject to laws and regulations [added: in many jurisdictions] governing government contracts, public procurement, and government [removed: reimbursements in many jurisdictions,] [added: reimbursements,] as to which the failure to comply could adversely affect our business.

- [removed: In addition] [added: We are exposed] to [added: risks associated with] potential litigation, arbitration, and governmental proceedings, [removed: we are exposed to risks associated with] [added: including] product liability claims that have been and may be brought against [removed: us or as a result of the actions or inactions of our customers or third parties that are outside of our control.][added: us.]

[removed: - Our] [added: Our] certificate of incorporation provides that certain [added: state and federal] courts in the State of Delaware [removed: or the federal district courts of the United States] will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or [removed: employees.][added: employees.]

- We have significant postretirement benefit [removed: liabilities, including pension, healthcare, and life insurance benefits obligations,] [added: liabilities] and [removed: the] [added: their] actual costs and related cash flows [removed: of these obligations] are uncertain and could exceed current estimates.

[removed: - Changes] [added: Changes] in foreign currency exchange rates, equity prices, and interest rates, and unfavorable changes in economic conditions or uncertainties that [removed: effect] [added: affect] the capital [removed: markets] [added: markets,] could adversely affect our financial [removed: performance.][added: performance.]

You should carefully consider the following risks and other information in this Annual Report on Form 10-K in evaluating [removed: GE HealthCare] [added: us] and [removed: GE HealthCare’s] [added: our] common stock.

We face substantial competition from international and domestic companies of all [removed: sizes;] [added: sizes, and] these competitors often differ across our businesses.

Competition is primarily focused on [removed: cost effectiveness, price,] [added: cost-effectiveness, pricing,] service, product performance, and technological innovation.

- the development of new technology, the application of known or unknown technology, advances in medicine, or new developments in the treatment or diagnosis of disease that transform our industry or render a product [added: or product] line obsolete;

- a failure to successfully enter new [added: or emerging] geographic or adjacent product [added: markets, including as a result of pricing pressures from local and international competitors in those] markets;

The implementation of localization requirements and [added: the] other government policies in certain [removed: geographies, driven by support of local industry, security of supply,] [added: geographies such as China] and [removed: incentives for technological breakthroughs, could negatively affect] [added: Russia creates a risk that, if we do not localize] our [added: products or operations to meet such requirements, we could lose] market [removed: share,] [added: share and experience adverse effects on our] business results, cash flows, and financial condition.

Increased competition from ISOs and evolving regulatory and legislative policies could adversely impact our business and [removed: results of operations.][added: financial results.]

[removed: In] [added: For example, in] the [removed: United States] [added: U.S.] and Europe, ISOs continue to seek access to OEM service tools, parts, documents, software updates, and training.

Specifically, [removed: in 2021,] the Librarian of Congress in the [removed: United States] [added: U.S. has] authorized a copyright act exemption that allows [removed: unregulated] third-party repair companies to circumvent OEM copyright protections on software in its medical imaging device or system if circumvention is necessary to diagnose, maintain, or repair such device or system.

[removed: Furthermore,] [added: Similarly,] regulatory and legislative changes, such as the adoption of right-to-repair laws in the [removed: United States] [added: U.S.] and elsewhere, could further strengthen the ability of ISOs to obtain valuable service contracts and [removed: directly] compete with us in the services area.

In recent years, U.S. [added: and some international] healthcare industry participants, including distributors, manufacturers, suppliers, healthcare providers, insurers, and pharmacy chains, have consolidated or formed strategic alliances.

We expect the U.S. [added: and to some extent the international] healthcare industry to continue to change in the future.

We generate the majority of our revenue outside of the [removed: United States] [added: U.S.] and our business is sensitive to global economic conditions.

Slower global economic growth; [removed: actual or anticipated default on sovereign debt;] volatility in the currency and credit markets; inflationary pressures; high levels of unemployment or underemployment; reduced levels of capital expenditures; changes or anticipation of potential changes in government fiscal, tax, import and export, [added: trade,] and monetary policies; changes in capital requirements for financial institutions; disruptions in the financial services industry; [added: actual or anticipated default on sovereign debt;] government deficit reduction and budget negotiation dynamics; sequestration; austerity measures; and other challenges that affect the global economy could adversely affect us and our customers, suppliers, and channel partners.

The rise of economic nationalism could make it more difficult for us to attract new customers, retain existing customers, continue to produce and source in an optimal manner, or maintain sales at existing levels, both in the [removed: United States] [added: U.S.] and in other countries.

Geopolitical and economic risks have increased over the past few years in many regions of the world, including in the [removed: United States.][added: U.S. Our operations expose us to the risk that increased trade protectionism may adversely affect our business.]

Growing tensions, protectionist trade policies, and tariffs may also lead to a fragmentation of the global economy, [added: operational and logistical shifts in supply chains that may lead to higher costs and longer lead times,] a general reduction of international trade in goods and services, and a reduction in the integration of financial markets, any of which could materially and adversely affect our business results, cash flows, financial condition, or prospects.

Further risks stem from [added: ongoing and future] geopolitical tensions and volatility [removed: (such as in Cuba, Iran, Syria, Russia, North Korea,] and [removed: Israel and surrounding areas), other future conflicts that may arise, and] economic sanctions imposed relating to regions and persons included on sanctioned party lists.

In particular, the conflict between Ukraine and Russia [added: and resulting sanctions and other restrictions imposed by the U.S., the EU, and Russia] may negatively impact our [removed: revenue] [added: business and financial results] to the extent the conflict and the sanctions significantly impact our ability to sell products or services to customers in the affected [removed: regions,] [added: countries,] collect receivables from such customers, or repatriate cash we do collect.

Given the nature of our products, we do not believe that the current sanctions and other measures imposed by the [removed: United States] [added: U.S.] and other countries preclude us from conducting business in the region.

However, these sanctions have [removed: made] [added: made,] and will continue to [removed: make] [added: make,] it more burdensome and costly to serve customers in [removed: these regions.][added: the region.]

The implementation of these measures affected our ability to supply customers in Russia [removed: during the years ended December 31, 2024 and 2023] [added: in 2025] and [removed: will] [added: is expected to] continue to do so as we confirm applicability of the U.S. License Exception to our transactions and continue to obtain licenses.

There is no guarantee we will obtain all of the licenses for which we [removed: applied,] [added: apply,] that any approvals we obtain will be on a timely basis, or that our business in Russia will not be further disrupted due to evolving legal or operational considerations.

The [removed: lead up] [added: lead-up] to these elections and their outcomes could result in sharp shifts in domestic, economic, and foreign policy approaches or even result in new or deepening geopolitical conflicts.

An uncertain economic environment may also adversely affect our customers’ budgets and may result in pricing pressure, requests for extended warranty provisions, [added: and] cancellation of service contracts, and could make it more difficult for us to collect outstanding receivables, especially in emerging markets.

Any of these risks could have a material adverse effect on our [removed: business results,] [added: business, results of operations,] cash flows, financial condition, [removed: prospects, and the market price of our securities.][added: or prospects.]

Some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events, or contingencies have occurred in the past and instead reflect our beliefs and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future.

This summary of risks is intended to provide an overview of the principal risks we face and should not be considered a substitute for a review of the more detailed risk factors discussed immediately following this summary.

*Industry and Economic Risks*

- We operate in highly competitive markets.

- Our business is subject to the effects of global geopolitical and economic instability and public health crises.

*Business and Operational Risks*

- Our business strategy could be adversely affected if we are unable to successfully complete strategic transactions or manage our collaboration, joint venture, or similar arrangements.

We cannot guarantee that these investments will generate new offerings, attract customers, or generate sufficient revenue.

- We manufacture and sell products that rely upon software and computer systems to operate properly and process and store confidential information.

Our business could be adversely affected by increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted cybercrimes, and our inability to obtain, maintain, protect, or effectively enforce our IP rights.

*Regulatory and Legal Risks*

- Our business operations are subject to extensive laws and regulations, including with regard to the development, authorization and commercialization of our products, as well as anti-corruption and anti-bribery laws, anti-kickback and false claims laws, antitrust and competition laws, privacy and information security laws, and applicable tax laws.

Any changes to or violations of these laws and regulations could have a material adverse effect on our business.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

*General Risks*

- Our existing indebtedness, and any additional indebtedness that we may incur, could have important consequences for our business.

- the performance, capability, and integrity of third parties, including due to their financial instability or their compliance or regulatory failures;

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Both the U.S. and international markets have experienced and may continue to experience inflationary pressures.

For example, during 2025, the U.S. imposed a variety of new tariffs on most imports from all countries in the world.

This in turn prompted several countries to announce tariffs on U.S. imports.

While the situation continues to be fluid, tariffs materially impacted our profitability and cash flows in 2025, primarily the bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers.

Should the tariffs continue at formally communicated levels, we expect to continue to see a material impact to our financial results through the incurrence of additional costs.

Additional tariffs or other trade restrictions by the U.S. or other countries where we do significant business, or other restrictions on specific industries, such as pharmaceuticals, could further materially impact our results in the future.

We do not expect that our mitigation actions will fully offset the additional costs or other negative impacts resulting from the tariffs.

In addition, current changes and uncertainties in global tariffs are causing volatility in our cost positioning in some international markets.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

For example, China has implemented volume-based procurement processes to constrain healthcare costs.

See Note 8, "Acquisitions, Goodwill, and Other Intangible Assets" for a discussion of the acquisitions we completed or have entered into in 2025.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Additionally, dispositions of non-core assets or businesses could involve difficulties in the separation of operations, services, products, and employees, the disruption of our business, and the potential loss of key employees.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

For example, in 2025, China significantly tightened its export controls on rare earth minerals.

Some, but not all, of these restrictions were temporarily suspended after trade negotiations with the U.S. in October 2025.

For example, we rely on contract manufacturing organizations to produce certain of our molecular imaging pharmaceutical products.

Failure by third-party suppliers to maintain sufficient manufacturing capacity for our products could create shortages or delay fulfilling orders.

We cannot guarantee that the mitigation strategies we employ will be successful or that we will be able to alter our strategies or develop new strategies if and as needed.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

These risks relate to our business; competition; the healthcare industry; data privacy and cybersecurity; laws surrounding quality, regulation, and compliance; geopolitical megatrends; financing and capital markets activities; and our common stock.

Some of the more significant challenges and risks we face include the following:

- We operate in highly competitive markets, competition may increase in the future, and our industry may be disrupted, requiring us to lower prices or resulting in a loss of market share, and our inability to successfully complete strategic transactions could adversely affect our business.

- Global geopolitical instability, such as continuing uncertainties and challenging conditions in regional economies and global economic instability, such as public health crises, have and could in the future adversely affect our business, customers, and suppliers.

- If we do not successfully manage our collaboration arrangements, licensing arrangements, joint ventures, or strategic alliances with third parties, we may not realize the expected benefits from such arrangements, which could adversely affect our business.

- Our research and development efforts may not succeed in developing commercially successful products and technologies, which could adversely affect our business.

- Our business operations are tightly regulated by the U.S. FDA and equivalent global agencies and are subject to extensive laws and regulations, including the Foreign Corrupt Practices Act (the “FCPA”), similar anti-corruption and anti-bribery laws, anti-kickback and false claims laws, antitrust and competition laws, and stringent privacy laws and information securities regulations, and applicable tax laws and any changes thereto or violations thereof could have a material adverse effect on our business.

- Developments following regulatory authorization, including results in post-approval device or pharmaceutical Phase 4 trials or other studies, could adversely affect sales or decrease demand for our medical devices or pharmaceutical products.

- Complying with our requirements under our debt instruments could adversely affect our business, results of operations, cash flows, and financial condition.

- Future material impairments in the value of our long-lived assets, including goodwill, could adversely affect our business.

- Certain of our directors and employees may have actual or potential conflicts of interest because of their financial interests in GE or because of their previous or continuing positions with GE.

- Certain provisions in our certificate of incorporation, bylaws, and Delaware law may discourage takeovers.

- We or GE may fail to perform under various transaction agreements executed as part of the Spin-Off.

Any of the following risks could materially and adversely affect GE HealthCare’s business, financial condition, or results of operations.

For example, policies in countries such as China and Russia that require the purchase of locally manufactured products or that are favorable to locally-based manufacturers, and our ability or decision to meet the requirements of such policies, may affect customer purchasing decisions and may have an adverse effect on our business, operations, or financial results.

Additionally, our HealthCare Financial Services business is subject to various laws, rules, and regulations administered by authorities in jurisdictions where it does business, including the United States, Canada, China, France, Germany, the United Kingdom, and certain countries in Latin America.

Both the United States and international markets experienced significant inflationary pressures in 2023 and, to a lesser extent, 2024, and inflation rates in the United States, as well as in other countries in which we operate, may continue at elevated levels for the near term.

In response, the Federal Reserve in the United States and other central banks in various countries have raised interest rates in response to concerns about inflation which may have the effect of further increasing economic uncertainty.

Our business is affected by global geopolitical conditions.

For example, in March 2024, the government in China announced a new stimulus program (“2024 stimulus”) that includes the healthcare sector and is being implemented through China’s provinces.

In addition, an anti-corruption campaign directed at the healthcare sector remains ongoing.

Both of these factors contributed to delayed orders and sales in our China business throughout 2024.

While we expect the 2024 stimulus program to result in opportunities for our business in China in the longer term, it has had a short-term impact as provinces develop and announce their plans and customers begin to make purchasing decisions.

We expect the effects of the delay in the 2024 stimulus and the anti-corruption campaign to continue to impact our orders and sales in the near term, although we are unable to predict the exact duration or magnitude of the impact.

Our operations expose us to the risk that increased trade protectionism may adversely affect our business.

For example, in late 2024 and early 2025, the United States, China, and the European Union each announced either new tariffs, non-tariff barriers (principally related to participation in public procurement of healthcare equipment), or export controls.

Any of these risks, ensuing retaliation, or the further deterioration of trade relations between countries could make our offerings more expensive or non-competitive in the affected countries.

We are continuously monitoring economic, political, and geopolitical developments to assess any potential future impact that may arise.

We may not be successful in driving the global deployment and customer adoption of digital offerings characterized by digital applications and solutions.

By way of example, we were adversely affected by the inability of our suppliers to deliver components and raw materials on a timely basis in connection with the COVID-19 pandemic.

In addition, we cannot guarantee that the mitigation strategies we employ, such as internal and third-party risk management tools, maintaining objective evidence of our suppliers’ compliance with minimum viable quality standards and audits of conformance with these standards, conducting ongoing supplier and internal audits, developing resiliency plans, and investing in our internal data and analytic architecture, will be successful or that we will be able to alter our strategies or develop new strategies if and as needed.

Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted cyber crimes pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our business.

creating new attack methods for adversaries.

Having a diverse and inclusive workplace can also enhance our ability to attract and retain talent and is an important driver of our ability to compete and innovate.

As such, our inability to attract and retain diverse talent can have adverse consequences on our business.

Third-party organizations that provide information to investors on ESG matters have developed ratings processes for evaluating companies on their respective approaches.

We are subject to legal and regulatory requirements that focus on our ESG positions, performance, and disclosures.

A failure to adequately meet regulatory expectations may result in non-compliance, the loss of business, reputational impacts, and an inability to attract and retain top talent.

industry standards, or competitors’ innovations or reverse engineering efforts.

If our Spin-Off from GE is determined to be a taxable transaction, it could result in significant tax liability to GE and its stockholders and we could have an indemnification obligation to GE, which could adversely affect our business, financial condition, cash flows, and results of operations.

The following discussion and analysis of our financial results should be read in conjunction with the consolidated [removed: and combined] financial statements and corresponding notes (the “financial statements”) included elsewhere in this Annual Report on Form 10-K.

The following discussion and analysis provide information management believes to be relevant to understanding the financial results of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) for the years ended December 31, [removed: 2024, 2023,] [added: 2025] and [removed: 2022.][added: 2024.]

On January 3, 2023, [removed: the] General Electric Company, which now operates as GE Aerospace (“GE”), completed the spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”).

Percentages presented are calculated from the underlying whole-dollar [removed: amounts, and] [added: amounts and,] unless otherwise stated, represent changes year-over-year.

[removed: Following this realignment, the Company continues to have] [added: GE HealthCare’s operations are organized and managed through] four reportable segments: Imaging, Advanced Visualization [removed: Solutions,] [added: Solutions (“AVS”),] Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics [removed: (“PDx”).][added: (“PDx”), and we assessed their performance using Segment revenues and Segment EBIT.]

We had [removed: $162] [added: $214] million and [removed: $153] [added: $162] million of assets in, or directly related to, Russia and Ukraine as of December 31, [removed: 2024] [added: 2025] and December 31, [removed: 2023,] [added: 2024,] respectively, none of which are subject to sanctions that impact the carrying value of the assets.

We generated revenues of [removed: $363 million, $340 million,] [added: $353 million] and [removed: $395] [added: $363] million from customers in these two countries for the years ended December 31, [removed: 2024, 2023,] [added: 2025] and [removed: 2022,] [added: 2024,] respectively.

The implementation of these measures affected our ability to supply customers in Russia during the years ended December 31, [removed: 2024] [added: 2025] and [removed: 2023] [added: 2024] and [removed: will] [added: is expected to] continue to do so as we confirm applicability of the U.S. License Exception to our transactions and continue to obtain licenses.

There is no guarantee we will obtain all of the licenses for which we [removed: applied,] [added: apply,] that any approvals we obtain will be on a timely basis, or that our business in Russia will not be further disrupted due to evolving legal or operational considerations.

[removed: The Board, together with management,] [added: We] will continue to assess whether developments related to the conflict have had, or are reasonably likely to have, a material impact on the Company.

Our [removed: revenues and] [added: revenues,] operating [removed: profits] [added: profits, and cash flows] vary from quarter to quarter.

| Consolidated [removed: and Combined] Statements of Income | | | | | | | | | For the years ended December 31 | | | | | | | | | | | |

| Sales of products | | | | | | | | | | | | $ | [removed: 13,075] [added: 13,661] | | $ | [removed: 13,127] [added: 13,075] | | [removed: $] | [removed: 12,044] | |

| Sales of services | | | | | | | | | | | | [removed: 6,597] [added: 6,964] | | | [removed: 6,425] [added: 6,597] | | | [removed: 6,297] | | |

| Total revenues | | | | | | | | | | | | [removed: 19,672] [added: 20,625] | | | [removed: 19,552] [added: 19,672] | | | [removed: 18,341] | | |

| Cost of products | | | | | | | | | | | | [removed: 8,271] [added: 8,942] | | | [removed: 8,465] [added: 8,271] | | | [removed: 7,975] | | |

| Cost of services | | | | | | | | | | | | [removed: 3,196] [added: 3,436] | | | [removed: 3,165] [added: 3,196] | | | [removed: 3,187] | | |

| Gross profit | | | | | | | | | | | | [removed: 8,205] [added: 8,248] | | | [removed: 7,922] [added: 8,205] | | | [removed: 7,179] | | |

| Selling, general, and administrative | | | | | | | | | | | | [removed: 4,269] [added: 4,225] | | | [removed: 4,282] [added: 4,269] | | | [removed: 3,631] | | |

| Research and development | | | | | | | | | | | | [removed: 1,311] [added: 1,260] | | | [removed: 1,205] [added: 1,311] | | | [removed: 1,026] | | |

| Total operating expenses | | | | | | | | | | | | [removed: 5,580] [added: 5,485] | | | [removed: 5,487] [added: 5,580] | | | [removed: 4,657] | | |

| Operating income | | | | | | | | | | | | [removed: 2,625] [added: 2,763] | | | [removed: 2,435] [added: 2,625] | | | [removed: 2,522] | | |

| Interest and other financial charges – net | | | | | | | | | | | | [removed: 504] [added: 440] | | | [removed: 542] [added: 504] | | | [removed: 77] | | |

| Non-operating benefit (income) costs | | | | | | | | | | | | [removed: (406)] [added: (288)] | | | [removed: (382)] [added: (406)] | | | [removed: (5)] | | |

| Other (income) expense – net | | | | | | | | | | | | [removed: (55)] [added: (157)] | | | [removed: (86)] [added: (55)] | | | [removed: (62)] | | |

| Income [removed: from continuing operations] before income taxes | | | | | | | | | | | | [removed: 2,581] [added: 2,768] | | | [removed: 2,361] [added: 2,581] | | | [removed: 2,512] | | |

| Benefit (provision) for income taxes | | | | | | | | | | | | [removed: (531)] [added: (614)] | | | [removed: (743)] [added: (531)] | | | [removed: (563)] | | |

| Net income | | | | | | | | | | | | [removed: 2,050] [added: 2,154] | | | [removed: 1,614] [added: 2,050] | | | [removed: 1,967] | | |

| Net (income) loss attributable to noncontrolling interests | | | | | | | | | | | | [removed: (57)] [added: (70)] | | | [removed: (46)] [added: (57)] | | | [removed: (51)] | | |

| Net income attributable to GE HealthCare | | | | | | | | | | | | $ | [removed: 1,993] [added: 2,084] | | $ | [removed: 1,568] [added: 1,993] | | [removed: $] | [removed: 1,916] | |

| | | | | | | | | | | | | | | | | | | [removed: 2024] [added: 2025] | | | [removed: 2023] [added: 2024] | | | [removed: 2022] | | | [removed: 2024 vs. 2023] % change | | | [removed: 2023 vs. 2022 % change] | | | [removed: 2024 vs. 2023] % [removed: organic* change] [added: organic* change] | | | [removed: 2023 vs. 2022 % organic* change] | | |

| Other(1) | | | | | | | | | | | | | | | | | | [removed: 52] [added: 40] | | | [removed: 66] [added: 52] | | | [removed: 60] | | | | | | | | | | | | | | |

| Total revenues | | | | | | | | | | | | | | | [removed: | | |] $ | [removed: 19,672 | | $ | 19,552] [added: 20,625] | | $ | [removed: 18,341 | | 1% |] [added: 19,672] | | [removed: 7%] | | | [removed: 1%] [added: 4.8%] | | | [removed: 8%] | | |

| United States and Canada (“USCAN”) | | | | | | | | | | | | | | | $ | [removed: 8,981] [added: 9,531] | | $ | [removed: 8,551] [added: 8,981] | | [removed: $] | [removed: 8,130] | | [removed: 5%] [added: 6.1%] | | | [removed: 5%] | | |

| Europe, the Middle East, and Africa (“EMEA”) | | | | | | | | | | | | | | | [removed: 5,051] [added: 5,425] | | | [removed: 5,058] [added: 5,051] | | | [removed: 4,684] | | | [removed: —%] [added: 7.4%] | | | [removed: 8%] | | |

| Rest of World | | | | | | | | | | | | | | | [removed: 3,280] [added: 3,418] | | | [removed: 3,158] [added: 3,280] | | | [removed: 2,996] | | | [removed: 4%] [added: 4.2%] | | | [removed: 5%] | | |

| Total revenues | | | | | | | | | | | | | | | $ | [removed: 19,672 | | $ | 19,552] [added: 20,625] | | $ | [removed: 18,341 | | 1% |] [added: 19,672] | | [removed: 7%] [added: 4.8%] | | |

*For the year ended December 31, [removed: 2024*][added: 2025*]

- Rest of World revenues were [removed: $3,280] [added: $3,418] million, growing [removed: 4%] [added: 4.2%] or [removed: $122] [added: $138] million with growth in [removed: all segment] [added: PDx, inclusive of NMP] revenues, [added: and Imaging revenues,] partially offset by unfavorable foreign currency impacts.

*For the year ended December 31, [removed: 2023*][added: 2025*]

For additional information on the year ended December 31, 2023 and year-over-year comparisons to December 31, 2024, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Refer to Note 19, “Related Parties and Transition Services Agreement” for further information.

*Global Trade and Macroeconomic Environment*

Throughout 2025, the U.S. imposed a variety of new tariffs on most imports from all countries in the world.

This in turn prompted several countries to announce tariffs on U.S. imports.

While the situation continues to be fluid, tariffs materially impacted our Operating income by approximately $245 million and cash flows by approximately $285 million for the year ended December 31, 2025, primarily the bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers.

Should the tariffs continue at formally communicated levels, we expect to continue to see a material impact to our financial results.

Additional tariffs or other trade restrictions by the U.S. or other countries where we do significant business, or other restrictions on specific industries, such as pharmaceuticals, could further materially impact our results in the future.

While we are taking actions to mitigate the impact of tariffs, we do not expect that our mitigation actions will fully offset the additional costs or other negative impacts resulting from the tariffs.

We continue to monitor the global markets in which we operate for changes in customer behavior, changes in government spending and reimbursement, and indirect impacts from the tariffs.

Should these factors dampen economic growth, slow global trade, or impact inflation, we could see adverse impacts to our business as our customers adapt to the change in economic environment.

We also continue to monitor potential impacts on purchasing decisions by both public and private customers in China and other markets as a result of the current trade environment, as well as other actions related to tariffs and trade frictions, investigations, or activities that could similarly increase our costs or otherwise impact our business.

In addition, if negative sentiment towards U.S. companies influences the purchasing decisions of global customers, our business could be impacted materially.

We believe the focus of government policy in China is on expanding access to healthcare.

In addition, our investments to address clinical needs, localization, and commercial infrastructure should benefit our business in China in the long term.

However, we continue to monitor developments in the China market, including increased competition from local companies and the prevalence of Volume Based Procurement policies, both of which have impacted our orders and revenues and may continue to do so.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

*Geopolitical Conflicts*

Geopolitical instability, across multiple regions, could adversely impact our operations, supply chains, and logistics.

These events may result in increased costs, delays in product deliveries, and challenges in maintaining service levels in affected areas.

While these events have not materially impacted our operations, we continue to monitor these developments closely.

*Recent U.S. Legislation*

On July 4, 2025, the One Big Beautiful Bill Act was signed into U.S. law, which includes significant changes to the federal income tax system.

The changes did not have a material impact to the Company’s tax provision for the year ended December 31, 2025.

___________________

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| | | | | | | | | | | | | 2025 | | | 2024 | | | | | |

| | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | |

| Imaging | | | | | | | | | | | | | | | | | | $ | 9,245 | | $ | 8,855 | | | | | 4.4% | | | | | | 3.8% | | | | | |

| AVS | | | | | | | | | | | | | | | | | | 5,354 | | | 5,131 | | | | | | 4.3% | | | | | | 3.8% | | | | | |

| PCS | | | | | | | | | | | | | | | | | | 3,086 | | | 3,125 | | | | | | (1.2)% | | | | | | (1.5)% | | | | | |

| PDx | | | | | | | | | | | | | | | | | | 2,900 | | | 2,508 | | | | | | 15.6% | | | | | | 8.8% | | | | | |

| China region | | | | | | | | | | | | | | | 2,251 | | | 2,360 | | | | | | (4.6)% | | | | | |

Sales of products increased 4.5% or $586 million primarily driven by strong growth in PDx, Imaging, and AVS revenues.

Sales of services increased 5.6% or $368 million primarily driven by growth in new and existing customer contractual agreements.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

- Imaging segment revenues were $9,245 million, growing 4.4% or $390 million, with growth in the USCAN and EMEA regions, partially offset by continued pressure in the China market;

- AVS segment revenues were $5,354 million, growing 4.3% or $222 million with strength in the U.S. market, partially offset by continued pressure in the China market;

- PCS segment revenues were $3,086 million, decreasing 1.2% or $38 million, largely driven by a decline in Life Support Solutions revenues; and

| | | | | | |

| --- | --- | --- | --- | --- | --- |

| Part II. Financial Information | | | | | |

| Index | | | | | |

| Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) | | | Page | | |

| [Trends and Factors Impacting Our Performance](#ic5f48a2b80264b159361fdd8ef5e37cf_106) | | | [39](#ic5f48a2b80264b159361fdd8ef5e37cf_106) | | |

| [Summary of Key Performance Measures](#ic5f48a2b80264b159361fdd8ef5e37cf_109) | | | [40](#ic5f48a2b80264b159361fdd8ef5e37cf_109) | | |

| [Results of Operations](#ic5f48a2b80264b159361fdd8ef5e37cf_112) | | | [41](#ic5f48a2b80264b159361fdd8ef5e37cf_112) | | |

| [Results of Operations – Segments](#ic5f48a2b80264b159361fdd8ef5e37cf_115) | | | [44](#ic5f48a2b80264b159361fdd8ef5e37cf_115) | | |

| [Non-GAAP Financial Measures](#ic5f48a2b80264b159361fdd8ef5e37cf_118) | | | [45](#ic5f48a2b80264b159361fdd8ef5e37cf_118) | | |

| [Liquidity and Capital Resources](#ic5f48a2b80264b159361fdd8ef5e37cf_121) | | | [50](#ic5f48a2b80264b159361fdd8ef5e37cf_121) | | |

| [Recently Issued Accounting Pronouncements](#ic5f48a2b80264b159361fdd8ef5e37cf_124) | | | [52](#ic5f48a2b80264b159361fdd8ef5e37cf_124) | | |

| [Critical Accounting Estimates](#ic5f48a2b80264b159361fdd8ef5e37cf_127) | | | [52](#ic5f48a2b80264b159361fdd8ef5e37cf_127) | | |

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

For further information regarding the Spin-Off, refer to Note 1, “Organization and Basis of Presentation.”

Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.

The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”).

These segments have been identified based on the nature of the products sold and how the Company manages its operations.

Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure.

We continue to monitor developments in the market in China.

In March 2024, the government in China announced a new stimulus program (“2024 stimulus”) that includes the healthcare sector and is being implemented through China’s provinces.

In addition, an anti-corruption campaign directed at the healthcare sector remains ongoing.

Both of these factors contributed to delayed orders and sales in our China business throughout 2024.

We expect the 2024 stimulus program will result in opportunities for our business in China in the longer term, but it has had a short-term impact as provinces develop and announce their plans and customers begin to make purchasing decisions.

We expect the effects of the delay in the 2024 stimulus and the anti-corruption campaign to continue to impact our orders and sales in the near term, although we are unable to predict the exact duration or magnitude of the impact.

We expect both of these impacts to be temporary, and we believe the focus of government policy in China on expanding access to healthcare will benefit our business in China in the long term.

*Tariffs*

In February 2025, the United States imposed additional tariffs on products from China.

These tariffs, and any future tariffs, including on products from Mexico or Canada, by the United States or other countries, will likely result in additional costs to us.

The impact of tariffs will depend on various factors including the timing, amount, scope, and nature of the tariffs, and any mitigating actions we implement.

*Tax Valuation Allowances*

Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.

We evaluate the recoverability of these future tax deductions and credits by evaluating all available positive and negative evidence.

We have a valuation allowance against certain U.S. and foreign deferred tax assets and will release the valuation allowance when there is sufficient positive evidence to support a conclusion that it is more likely than not the deferred tax assets will be realized.

For additional information regarding our income taxes, see Note 11, “Income Taxes.”

OPERATION AS A STAND-ALONE COMPANY.

*Financial Presentation Under GE Ownership*

GE HealthCare utilized allocations and carve-out methodologies through the date of the Spin-Off to prepare historical combined financial statements.

The combined financial statements herein for periods prior to the Spin-Off may not be indicative of our future performance, do not necessarily include the actual expenses that would have been incurred by us, and may not reflect our results of operations, financial position, and cash flows had we been a separate, stand-alone company during the historical periods presented.

For additional information, see Note 1, “Organization and Basis of Presentation.”

The potential [removed: decrease] [added: increase] in fair value of our foreign currency derivative contracts from a 10% decrease in USD spot rates against other applicable currencies would have been [removed: $82] [added: $111] million as of December 31, [removed: 2024.][added: 2025.]

The sensitivity analysis assumes a uniform weakening of USD spot rates against the other applicable currencies, compared to the actual exchange rates applied as of December 31, [removed: 2024,] [added: 2025,] with all other factors remaining constant.

See Note 2, “Summary of Significant Accounting Policies” for net gains (losses) from foreign currency transactions for the years ended December 31, [added: 2025,] 2024, [removed: 2023,] and [removed: 2022.][added: 2023.]

As of December 31, [removed: 2024,] [added: 2025,] we have [removed: $8,250] [added: $9,500] million [added: outstanding principal] of fixed-rate [removed: debt] [added: senior unsecured notes] and [removed: $750] [added: $500] million outstanding [added: principal] on the Term Loan Facility which carries a variable interest rate.

As of December 31, [removed: 2024,] [added: 2025,] we have [removed: $2,889] [added: $4,512] million of Cash, cash equivalents, and restricted cash, of which [removed: $1,885] [added: $3,445] million is invested in short-term investments that generate income based on variable interest rates.

A hypothetical change of interest rates by 100 basis points would increase or decrease our annual interest expense by approximately [removed: $35] [added: $32] million, partially offset by the change in interest income from our cash investments.

As of December 31, [removed: 2024,] [added: 2025,] we executed an aggregate notional amount of interest rate swap contracts to synthetically convert $2,700 million of our senior unsecured notes from fixed rates to variable rates as part of our interest rate risk management strategy.

If the costs of certain commodities or of energy, shipping, or transportation increase and we are unable to pass along these costs to our customers, our [removed: profit margins] [added: financial results] would be adversely affected.

Furthermore, increasing our prices to our customers could result in long-term sales declines or loss of market share if our customers find alternative suppliers, which could [added: also] have a material adverse effect on our [removed: results of operations.][added: financial results.]

As of December 31, [removed: 2024,] [added: 2025,] we have [removed: $260] [added: $248] million of deferred compensation liabilities subject to the risk of changes in equity prices.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

We may from time to time engage in hedging transactions to reduce the impact to earnings from commodity price fluctuations.

The impact of commodity hedges is recognized in earnings in the applicable current period.

GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” [added: “us,”] or “we”) is a [removed: trusted partner and] leading global healthcare solutions [removed: provider, innovating] [added: provider of advanced] medical technology, pharmaceutical diagnostics, and [removed: integrated, cloud-first AI-enabled solutions, services,] [added: AI, cloud] and [removed: data analytics.][added: software solutions that help clinicians tackle the world’s most complex diseases.]

We have approximately [removed: 53,000] [added: 54,000] colleagues dedicated to our [removed: mission] [added: purpose] to create a world where healthcare has no limits.

This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, [removed: deeply embedded in] [added: supported by our] lean [removed: continuous improvement.][added: business system, Heartbeat.]

We generate revenue from the sale of medical devices, consumable products, service capabilities, and [removed: digital] [added: AI-enabled cloud and software] solutions.

We serve customers in over 160 countries with a global team of approximately [removed: 9,800] [added: 9,700] sales professionals and [removed: 8,300] [added: 8,900] field service engineers.

Our customers are [removed: healthcare providers] [added: hospitals, health systems,] and researchers, including public, private, [added: academic,] and [removed: academic] [added: government] institutions.

[removed: We are] [added: Our business is] organized into four [removed: business] segments that are aligned with the industries we serve: Imaging, Advanced Visualization Solutions (“AVS”), Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”).

Our [added: comprehensive] portfolio of solutions addresses the biggest challenges facing healthcare [removed: providers and patients] today, and [removed: helps drive] [added: is designed to advance care delivery for customers, reduce disease burden, enable] better patient [removed: outcomes] [added: outcomes,] and [removed: improved productivity] [added: drive sustainable growth] for [removed: customers.][added: the company.]

Our [removed: revenues and] [added: revenues,] operating [removed: profits] [added: profits, and cash flows] vary from quarter to quarter.

Our Imaging [removed: portfolio] [added: segment] includes five product lines and associated service capabilities: Molecular Imaging (“MI”), Computed Tomography (“CT”), Magnetic Resonance (“MR”), Women’s Health, and X-ray.

We offer a complete MI solution from cyclotrons, chemistry synthesis, positron emission tomography (“PET”), computed tomography (“PET/CT”), [added: single-photon emission computed tomography (“SPECT”),] PET/MR, and nuclear medicine to advanced digital and AI-enabled solutions.

Our [removed: Molecular Imaging] [added: MI] team works closely with the PDx segment and their innovations and collaborations with pharmaceutical companies.

Our comprehensive [removed: Computed Tomography] [added: CT] portfolio includes multi-purpose and specialty scanners.

Our [removed: Magnetic Resonance] [added: MR] portfolio includes scanners for a range of clinical capabilities through different bore sizes, magnetic field strengths, and scalable platforms.

Our AVS [removed: business] [added: segment] is focused on designing solutions that are aligned by specialties or care areas for specific clinical workflows to better serve the unique needs of our customers and improve patient outcomes.

The [removed: AVS segment has a] [added: product] portfolio [removed: that] serves customers across two core areas: Specialized Ultrasound and Procedural Guidance.

Specialized Ultrasound includes Comprehensive Care [removed: Ultrasound,] [added: Ultrasound] and Women’s Health Ultrasound.

These systems include [removed: point of care] [added: point-of-care] and handheld ultrasound devices to support clinical decision-making throughout various care pathways in diverse sites of care.

[removed: This includes] [added: Our integrated portfolio of] ultrasound systems used to assess the structure and function of the [removed: heart,] [added: heart] as well as real-time [removed: advanced] X-ray [removed: imaging that integrates with ultrasound] [added: systems, combines advanced imaging, workflow intelligence,] and [removed: other imaging] [added: ergonomic designs, to support healthcare providers in delivering care with greater confidence] and [removed: diagnostic systems.][added: efficiency.]

- Surgical Innovations products are used in the operating environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be easily maneuverable in [removed: crowded] operating rooms and adaptable for various surgical procedures.

Each clinical area is supported with [removed: our] digital and [removed: AI-enabled ultrasound] [added: AI] solutions [removed: that are] designed to deliver [removed: optimal, simplified, and scalable clinical] [added: optimal workflows] and [removed: operational workflows.][added: increase efficiency.]

Our equipment, [removed: digital,] [added: software,] and AI solutions are complemented by service offerings that are highly regionalized according to local requirements, varying customer needs, and cross-modality service strategies.

Our PCS [removed: portfolio] [added: segment] serves care teams and healthcare systems across multiple patient care needs including Monitoring Solutions and Life Support Solutions.

Monitoring Solutions includes Patient [removed: Monitoring, Diagnostic Cardiology, Consumables and Services portfolio,] [added: Monitoring] and [removed: Digital Solutions.][added: Diagnostic Cardiology.]

- Our [removed: flexible] Patient Monitoring solutions enable clinicians to flex care based on a patient’s acuity and across the care continuum.

- [removed: In] [added: Our] Diagnostic [removed: Cardiology, we offer] [added: Cardiology portfolio offers] electrocardiogram (“ECG” or “EKG”) [removed: solutions, that] [added: solutions which] are [removed: usually] [added: typically] the first diagnostic [removed: tool] [added: tools] to detect cardiovascular disease, a leading cause of death globally.

- Our Consumables [removed: and Services] portfolio [removed: consists of approximately 1,000 consumables that are] [added: offers both clinical and non-clinical accessories] used throughout the hospital primarily with our monitors and therapy devices, such as blood pressure, ECG, pulse oximetry, temperature, respiratory rate, blood oxygen level, and brain activity.

Our service offerings are flexible and can range from preventative maintenance to comprehensive, onsite biomedical service engineering [removed: contracts.][added: contracts for both GE HealthCare and non-GE HealthCare installed base.]

- [removed: The Patient Care] [added: Our Digital] Solutions portfolio [removed: also] includes [removed: digital] solutions that provide clinical decision support in acute and other care settings, simplifying clinical and operational workflows to drive efficiencies and helping improve delivery of precision [removed: medicine] [added: care] and patient outcomes.

- Our Maternal Infant Care [added: portfolio offers] products [added: that] are used in the labor and delivery department to monitor important maternal and fetal parameters, and in neonatal intensive care to assist in critical care for newborns.

- [added: Our] Anesthesia [removed: products offer] [added: portfolio offers] life support solutions via ventilation technology and are used by anesthesiologists and nurse anesthetists to ventilate and deliver general anesthetic drugs to patients during surgeries.

[removed: GE HealthCare is a leading supplier of] [added: Our PDx segment supplies] contrast and radiopharmaceutical imaging agents to the global radiology and nuclear medicine industries.

PDx’s diagnostic agents are complementary to the imaging and ultrasound devices we offer, including CT, angiography and X-ray, MR, [removed: single-photon emission computed tomography (“SPECT”)] [added: SPECT,] and PET, and are also compatible with systems from other equipment vendors.

- Contrast media are pharmaceuticals that are administered to a patient [removed: prior to] [added: during] certain diagnostic scans in order to increase the visibility of tissues or structures [removed: during] [added: in] imaging exams.

Our unique combination of imaging equipment and pharmaceutical diagnostics enables building capabilities across disease states through diagnostic pharmaceuticals, hardware, software, and [removed: AI] [added: AI-enabled] and [removed: digital] [added: cloud] solutions.

Our business strategy includes the acquisition of technologies and businesses that [removed: expand] [added: expand, accelerate,] or complement our existing business.

We deliver value through innovative medical technology solutions across the patient care continuum (including screening, diagnosis, [removed: and] therapy, [added: and] monitoring) by leveraging hardware, software, AI, and digital technologies.

We engage in and sponsor clinical research and product development through collaborations with [removed: universities,] [added: academic institutions,] medical centers, and other organizations.

While, in aggregate, our patents and other IP are vital to our operations, we do not consider any single IP asset or group of assets to be of material importance to any segment or to the business as a [removed: whole; rather, we believe understanding our customers’ needs, technology expertise, and manufacturing know-how are critical for our business.][added: whole.]

In the industries we serve, we believe our primary global competitors include Siemens Healthineers, Philips Healthcare, [removed: Canon, Mindray, and] United Imaging, [added: Mindray, and Canon,] among others.

Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Ultrasound technologies are a meaningful component of both areas, reflecting their use across diagnostic, interventional, and surgical settings.

- CardioVascular and Interventional Solutions provides clinicians with innovative solutions that enhance diagnoses, intervention, treatment, and monitoring in therapeutic areas such as cardiology, peripheral vascular, neurology and oncology.

Together, these technologies facilitate image guided therapy across a full spectrum of interventional procedures.

Technologies like AI-guided ultrasound offer healthcare providers real-time guidance and step-by-step instructions to help clinicians conduct scans for cardiac assessments and capture high-quality images at the point-of-care.

Other digital automation and workflow solutions across the AVS portfolio can help reduce imaging barriers and repetitive tasks, increase standardization, and expand collaborative capacity.

Both Monitoring Solutions and Life Support Solutions include services, consumables, and digital applications.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Our broad portfolio of connected devices and digital solutions is complemented by a comprehensive suite of service offerings.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

We employ approximately 11,100 engineers and scientists worldwide, including hardware, systems, and software engineers and personnel focused on clinical research.

We foster a culture of belonging for all with high-performing teams that represent the global communities we serve.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

- Evolve our culture: We believe that achieving the intentional culture we desire is a key unlock to the highest performing organization we can be.

GE HealthCare’s sustainability strategy, guided by our Cultural Operating Principles, focuses on the following five pillars:

- Enable access to quality healthcare for more patients;

- Cultivate a workplace where all colleagues can thrive;

- Build a more sustainable, healthier future;

- Advance sustainable practices throughout the product lifecycle; and

- Deliver safe and secure products and services

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Our cloud, AI, edge computing, and software solutions must comply with stringent regulations, including certification requirements, in many of the countries in which our customers are located, particularly in relation to obtaining, using, storing, and transferring personal data, and such compliance is required before we can launch our offerings in the applicable countries.

Additionally, our use of AI to support business operations carries inherent risks related to data privacy, IP, and security, such as intended, unintended, or inadvertent transmission of proprietary, confidential, or sensitive information.

SALES & BUSINESS PRACTICES.

ADDITIONAL U.S. REGULATORY REQUIREMENTS.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Previously, Ms. Bankes served as President, Global Franchises at Alcon Inc. (NYSE: ALC), a global manufacturer of vision care products and surgical equipment, from March 2019 to April 2025.

Ms. Bankes has served on the board of Aurion Biotech, a clinical-stage regenerative medicine company, since February 2025 and served on the board of Atrion Corp. (Nasdaq: ATRI), a manufacturer of medical application products, from September 2023 to August 2024 and on the board of Apollo Endosurgery, Inc. (Nasdaq: APEN), a medical technology company, from April 2022 to April 2023.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

We operate at the center of the healthcare ecosystem, enabling precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine.

Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from screening and diagnosis to therapy and monitoring.

We have more than 125 years of experience and one of the strongest reputations in the global healthcare industry, built from our demonstrated record of delivering industry-defining innovation.

Precision care is expected to drive continued demand and the need for novel technologies and future innovation, as healthcare providers and researchers seek new solutions and tools for managing various disease states.

The pursuit of precision care opportunities significantly expands our addressable markets to include integrated diagnostics, AI and machine learning-based clinical decision support, highly personalized therapies enabled by more precise diagnostics, and remote patient monitoring.

The scale and breadth of our portfolio, combined with our innovation capabilities, position us to be a leading enabler of precision care.

Refer to Note 1, “Organization and Basis of Presentation” for further information regarding the Spin-Off.

We develop, manufacture, and market a broad portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients.

We have a large, global installed base of medical imaging, ultrasound, and patient monitoring systems.

Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.

The Ultrasound segment was subsequently renamed Advanced Visualization Solutions.

Following this realignment, the Company continues to have four reportable segments: Imaging, AVS, PCS, and PDx, as described below.

GE HealthCare is a global leader in medical imaging with a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions.

Our Imaging portfolio spans the care continuum and provides critical tools for clinicians, from initial screening and diagnosis, through therapeutic decision-making and monitoring of patient progression.

We also offer Picture Archiving and Communication Systems (“PACS”) and Radiological Information Systems to manage the storage and reporting of radiology images.

GE HealthCare is a global leader in ultrasound, image guided therapies, and interventional solutions with a broad portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases.

We continue to deliver innovative solutions to support interventional procedures, all with digital and AI-enabled solutions that help clinicians increase diagnostic confidence, while simplifying clinical and operational workflows.

- CardioVascular and Interventional Solutions provides clinicians with tools to diagnose, treat, and monitor cardiovascular conditions with precision and confidence as well as technologies to help assist clinicians and surgeons during open surgeries and minimally invasive and interventional procedures.

These technologies support planning, guiding, and assessing a variety of surgical procedures like cardiac interventions and those that involve insertion of devices like deep brain stimulators, spinal implants, and other neurological devices.

They are designed to increase efficiencies that support care for more patients by: providing AI-guided ultrasound to help clinicians of all experience levels acquire quality diagnostic images; eliminating keystrokes to shorten exam time; and providing clinical decision support tools.

GE HealthCare’s PCS segment is a leading global provider of medical devices, proprietary parameters and consumables, services, and digital solutions that acquire and transform complex clinical data into real-time visualization and clinical decision support to ease the way to more confident patient care and improve patient outcomes.

These solutions form a broad and integrated portfolio that support patient care needs and care teams within and beyond most acute healthcare environments.

Our broad portfolio of connected devices and digital solutions is complemented by a comprehensive suite of service offerings, including parts, labor, and training, as well as emerging data, analytics, and networking solutions enabled by AI to aid our customers in improving uptime and efficiency of their medical technology fleets.

Our strong portfolio of diagnostic agents and advanced global supply chain, combined with our imaging, cyclotron, and advanced visualization software, positions us to grow in existing markets as well as emerging adjacencies.

As part of the Spin-Off from GE, we secured IP specific to our business and GE granted us a license to use other IP required for our business.

We also entered into a long-term trademark license agreement with GE that enables GE HealthCare to continue building upon our brand.

“Risk Factors.”

We embrace a workplace where every voice makes a difference and helps build a healthier world.

- Evolve our culture: Our senior management team continues to lead our company through a transformational period, having completed the Spin-Off in January 2023 and now executing on our next phase as a public company.

We have approximately 900 union-represented manufacturing colleagues in the United States.

We have five focus areas that build upon our long-standing commitments to innovation, product quality, and integrity.

They are:

- Expanding access to quality healthcare;

- Promoting a culture of belonging for all;

- Mitigating our climate impact and improving resiliency;

- Advancing the circular economy and environmental design; and

- Protecting patient data and cybersecurity

GLOBAL HEALTHCARE COMPLIANCE.

| | | | | | | | | |

| Kenneth Stacherski | | | 54 | | | Chief Global Supply Chain and Service Officer | | |

For the fiscal year ended December 31, [removed: 2024][added: 2025]

[removed: ][added: ]

The aggregate market value of the outstanding common stock of the Registrant held by non-affiliates as of June [removed: 28, 2024,] [added: 30, 2025,] the last business day of the [removed: registrants] [added: registrant’s] most recently completed second fiscal quarter, was approximately [removed: $33] [added: $34] billion.

There were [removed: 457,298,310] [added: 455,749,767] shares of common stock with a par value of $0.01 per share outstanding as of [removed: February 6, 2025.][added: January 28, 2026.]

The definitive proxy statement relating to the registrant’s Annual Meeting of Stockholders, to be held May [removed: 28, 2025,] [added: 7, 2026,] is incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.

| [Forward-Looking [removed: Statements](#ic5f48a2b80264b159361fdd8ef5e37cf_19)] [added: Statements](#i3a6ad077e790432eb138c2b6742d6db7_19)] | | | | | | [removed: [3](#ic5f48a2b80264b159361fdd8ef5e37cf_19)] [added: [4](#i3a6ad077e790432eb138c2b6742d6db7_19)] | | |

| [Item [removed: 1A.](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] [added: 1A.](#i3a6ad077e790432eb138c2b6742d6db7_184)] | | | [Risk [removed: Factors](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] [added: Factors](#i3a6ad077e790432eb138c2b6742d6db7_184)] | | | [removed: [13](#ic5f48a2b80264b159361fdd8ef5e37cf_172)] [added: [14](#i3a6ad077e790432eb138c2b6742d6db7_184)] | | |

| [Item [removed: 1B.](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] [added: 1B.](#i3a6ad077e790432eb138c2b6742d6db7_187)] | | | [Unresolved Staff [removed: Comments](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] [added: Comments](#i3a6ad077e790432eb138c2b6742d6db7_187)] | | | [removed: [35](#ic5f48a2b80264b159361fdd8ef5e37cf_175)] [added: [35](#i3a6ad077e790432eb138c2b6742d6db7_187)] | | |

| [Item [removed: 1C.](#ic5f48a2b80264b159361fdd8ef5e37cf_178)] [added: 1C.](#i3a6ad077e790432eb138c2b6742d6db7_190)] | | | [removed: [Cybersecurity](#ic5f48a2b80264b159361fdd8ef5e37cf_178)] [added: [Cybersecurity](#i3a6ad077e790432eb138c2b6742d6db7_190)] | | | [removed: [35](#ic5f48a2b80264b159361fdd8ef5e37cf_178)] [added: [35](#i3a6ad077e790432eb138c2b6742d6db7_190)] | | |

| [Item [removed: 3.](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] [added: 3.](#i3a6ad077e790432eb138c2b6742d6db7_127)] | | | [Legal [removed: Proceedings](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] [added: Proceedings](#i3a6ad077e790432eb138c2b6742d6db7_127)] | | | [removed: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_136)] [added: [36](#i3a6ad077e790432eb138c2b6742d6db7_127)] | | |

| [Item [removed: 4.](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] [added: 4.](#i3a6ad077e790432eb138c2b6742d6db7_139)] | | | [Mine Safety [removed: Disclosures](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] [added: Disclosures](#i3a6ad077e790432eb138c2b6742d6db7_139)] | | | [removed: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_148)] [added: [36](#i3a6ad077e790432eb138c2b6742d6db7_139)] | | |

| [Item [removed: 5.](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] [added: 5.](#i3a6ad077e790432eb138c2b6742d6db7_196)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] [added: Securities](#i3a6ad077e790432eb138c2b6742d6db7_196)] | | | [removed: [36](#ic5f48a2b80264b159361fdd8ef5e37cf_184)] [added: [37](#i3a6ad077e790432eb138c2b6742d6db7_196)] | | |

| [Item [removed: 7.](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] [added: 7.](#i3a6ad077e790432eb138c2b6742d6db7_91)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operation](#ic5f48a2b80264b159361fdd8ef5e37cf_97)[s](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] [added: Operations](#i3a6ad077e790432eb138c2b6742d6db7_91)] | | | [removed: [38](#ic5f48a2b80264b159361fdd8ef5e37cf_97)] [added: [38](#i3a6ad077e790432eb138c2b6742d6db7_91)] | | |

| [Item [removed: 7A.](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] [added: 7A.](#i3a6ad077e790432eb138c2b6742d6db7_271)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] [added: Risk](#i3a6ad077e790432eb138c2b6742d6db7_271)] | | | [removed: [54](#ic5f48a2b80264b159361fdd8ef5e37cf_196)] [added: [50](#i3a6ad077e790432eb138c2b6742d6db7_271)] | | |

| [removed: [Item 8.](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] [added: Item 8.] | | | [Financial Statements and Supplementary [removed: Data](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] [added: Data](#i3a6ad077e790432eb138c2b6742d6db7_22)] | | | [removed: [56](#ic5f48a2b80264b159361fdd8ef5e37cf_22)] [added: [53](#i3a6ad077e790432eb138c2b6742d6db7_22)] | | |

| [Item [removed: 9.](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] [added: 9.](#i3a6ad077e790432eb138c2b6742d6db7_274)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] [added: Disclosure](#i3a6ad077e790432eb138c2b6742d6db7_274)] | | | [removed: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_262)] [added: [102](#i3a6ad077e790432eb138c2b6742d6db7_274)] | | |

| [Item [removed: 9A.](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] [added: 9A.](#i3a6ad077e790432eb138c2b6742d6db7_124)] | | | [Controls and [removed: Procedures](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] [added: Procedures](#i3a6ad077e790432eb138c2b6742d6db7_124)] | | | [removed: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_133)] [added: [102](#i3a6ad077e790432eb138c2b6742d6db7_124)] | | |

| [Item [removed: 9B.](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] [added: 9B.](#i3a6ad077e790432eb138c2b6742d6db7_142)] | | | [Other [removed: Information](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] [added: Information](#i3a6ad077e790432eb138c2b6742d6db7_142)] | | | [removed: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_151)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_142)] | | |

| [Item [removed: 9C.](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] [added: 9C.](#i3a6ad077e790432eb138c2b6742d6db7_280)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] [added: Inspections](#i3a6ad077e790432eb138c2b6742d6db7_280)] | | | [removed: [108](#ic5f48a2b80264b159361fdd8ef5e37cf_268)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_280)] | | |

| [Item [removed: 10.](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] [added: 10.](#i3a6ad077e790432eb138c2b6742d6db7_283)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] [added: Governance](#i3a6ad077e790432eb138c2b6742d6db7_283)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_271)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_283)] | | |

| [Item [removed: 11.](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] [added: 11.](#i3a6ad077e790432eb138c2b6742d6db7_286)] | | | [Executive [removed: Compensation](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] [added: Compensation](#i3a6ad077e790432eb138c2b6742d6db7_286)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_274)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_286)] | | |

| [Item [removed: 12.](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] [added: 12.](#i3a6ad077e790432eb138c2b6742d6db7_289)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] [added: Matters](#i3a6ad077e790432eb138c2b6742d6db7_289)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_277)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_289)] | | |

| [Item [removed: 13.](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] [added: 13.](#i3a6ad077e790432eb138c2b6742d6db7_292)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] [added: Independence](#i3a6ad077e790432eb138c2b6742d6db7_292)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_280)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_292)] | | |

| [Item [removed: 14.](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] [added: 14.](#i3a6ad077e790432eb138c2b6742d6db7_295)] | | | [Principal Accountant Fees and [removed: Services](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] [added: Services](#i3a6ad077e790432eb138c2b6742d6db7_295)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_283)] [added: [103](#i3a6ad077e790432eb138c2b6742d6db7_295)] | | |

| [Item [removed: 15.](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] [added: 15.](#i3a6ad077e790432eb138c2b6742d6db7_298)] | | | [Exhibits and Financial Statement [removed: Schedules](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] [added: Schedules](#i3a6ad077e790432eb138c2b6742d6db7_298)] | | | [removed: [109](#ic5f48a2b80264b159361fdd8ef5e37cf_286)] [added: [104](#i3a6ad077e790432eb138c2b6742d6db7_298)] | | |

| [Item [removed: 16.](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] [added: 16.](#i3a6ad077e790432eb138c2b6742d6db7_301)] | | | [Form 10-K [removed: Summary](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] [added: Summary](#i3a6ad077e790432eb138c2b6742d6db7_301)] | | | [removed: [111](#ic5f48a2b80264b159361fdd8ef5e37cf_289)] [added: [106](#i3a6ad077e790432eb138c2b6742d6db7_301)] | | |

These forward-looking statements may include, but are not limited to, statements about our [removed: business;] [added: business,] financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows; the impacts of macroeconomic and market [removed: conditions] [added: conditions, including the impact of tariffs] and [added: other trade restrictions, and] volatility on our [removed: business] [added: business,] operations, financial results, and financial position and on supply chains and the world economy; our cost structure; our funding and liquidity; the impacts on our business of manufacturing, sourcing, and supply chain management; the Russia and Ukraine conflict; [removed: our operations as a stand-alone company;] [added: share repurchases;] and risks related to foreign currency exchange, interest rates, and commodity price volatility.

Factors that could cause our actual results to differ materially from those described in our forward-looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of [removed: the conflict between Ukraine and Russia, tensions in the Middle East, and] changes in trade and tariff [removed: policy;] [added: policy, and international conflicts and tensions, including between Ukraine and Russia and in other regions;] public health crises, epidemics, and pandemics, and their effects on our business; changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for our products, services, or solutions and factors that affect that demand; [removed: the delayed China stimulus and] [added: developments in] the [removed: ongoing anti-corruption campaign;] [added: market in China;] our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions; our ability to successfully complete strategic transactions; the [added: actions or inactions of third parties with whom we partner and the various collaboration, licensing, and other partnerships and alliances we have with third parties; the] impacts related to our increasing focus on and investment in cloud, edge computing, artificial intelligence (“AI”), and software offerings; management of our supply chain and our ability to cost-effectively secure the materials we need to operate our business; disruptions in our operations; the [removed: actions or inactions of third parties with whom we partner and the various collaboration, licensing, and other partnerships and alliances we have with third parties; the] impact of potential information [removed: technology (“IT”),] [added: technology,] cybersecurity, or data security breaches; maintenance and protection of our intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; our ability to attract and/or retain key [removed: personnel] [added: talent] and qualified employees; [removed: environmental, social, and governance (“ESG”)] [added: increasing attention to sustainability] matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which we are subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability [removed: claims;] [added: claims or potential litigation, arbitration, or similar proceedings; and] our level of [removed: indebtedness, as well as our general ability to comply] [added: indebtedness and the impact of complying] with [added: the] covenants [removed: under] [added: and other terms of] our debt [removed: instruments, and any related effect] [added: instruments] on our [removed: business; and our ability to operate effectively as an independent, publicly traded company.][added: business.]

Please also see Item 1A, “Risk Factors” of this Annual Report on Form 10-K filed with the United States [added: (“U.S.”)] Securities and Exchange Commission (“SEC”) and any updates or amendments we make in future filings.

| [Item 1.](#i3a6ad077e790432eb138c2b6742d6db7_160) | | | [Business](#i3a6ad077e790432eb138c2b6742d6db7_160) | | | [5](#i3a6ad077e790432eb138c2b6742d6db7_160) | | |

| [Item 2.](#i3a6ad077e790432eb138c2b6742d6db7_193) | | | [Properties](#i3a6ad077e790432eb138c2b6742d6db7_193) | | | [36](#i3a6ad077e790432eb138c2b6742d6db7_193) | | |

| [Item 6.](#i3a6ad077e790432eb138c2b6742d6db7_199) | | | [\[Reserved\]](#i3a6ad077e790432eb138c2b6742d6db7_199) | | | [37](#i3a6ad077e790432eb138c2b6742d6db7_199) | | |

| | | | [Trends and Factors Impacting Our Performance](#i3a6ad077e790432eb138c2b6742d6db7_97) | | | [38](#i3a6ad077e790432eb138c2b6742d6db7_97) | | |

| | | | [Summary of Key Performance Measures](#i3a6ad077e790432eb138c2b6742d6db7_100) | | | [39](#i3a6ad077e790432eb138c2b6742d6db7_100) | | |

| | | | [Results of Operations](#i3a6ad077e790432eb138c2b6742d6db7_103) | | | [40](#i3a6ad077e790432eb138c2b6742d6db7_103) | | |

| | | | [Results of Operations – Segments](#i3a6ad077e790432eb138c2b6742d6db7_106) | | | [42](#i3a6ad077e790432eb138c2b6742d6db7_106) | | |

| | | | [Non-GAAP Financial Measures](#i3a6ad077e790432eb138c2b6742d6db7_109) | | | [43](#i3a6ad077e790432eb138c2b6742d6db7_109) | | |

| | | | [Liquidity and Capital Resources](#i3a6ad077e790432eb138c2b6742d6db7_112) | | | [47](#i3a6ad077e790432eb138c2b6742d6db7_112) | | |

| | | | [Recently Issued Accounting Pronouncements](#i3a6ad077e790432eb138c2b6742d6db7_115) | | | [48](#i3a6ad077e790432eb138c2b6742d6db7_115) | | |

| | | | [Critical Accounting Estimates](#i3a6ad077e790432eb138c2b6742d6db7_214) | | | [48](#i3a6ad077e790432eb138c2b6742d6db7_214) | | |

| | | | [Report of Independent Registered Public Accounting Firm - Deloitte & Touche LLP (PCAOB ID No.](#i3a6ad077e790432eb138c2b6742d6db7_205) 34) | | | [53](#i3a6ad077e790432eb138c2b6742d6db7_205) | | |

| | | | [Consolidated](#i3a6ad077e790432eb138c2b6742d6db7_25) [Statements](#i3a6ad077e790432eb138c2b6742d6db7_25) [of Income](#i3a6ad077e790432eb138c2b6742d6db7_25) | | | [56](#i3a6ad077e790432eb138c2b6742d6db7_25) | | |

| | | | [Consolidated](#i3a6ad077e790432eb138c2b6742d6db7_28) [Statements of Comprehensive Income (Loss)](#i3a6ad077e790432eb138c2b6742d6db7_28) | | | [57](#i3a6ad077e790432eb138c2b6742d6db7_28) | | |

| | | | [Consolidated Statements of Financial Position](#i3a6ad077e790432eb138c2b6742d6db7_31) | | | [58](#i3a6ad077e790432eb138c2b6742d6db7_31) | | |

| | | | [Consolidated](#i3a6ad077e790432eb138c2b6742d6db7_34) [](#i3a6ad077e790432eb138c2b6742d6db7_34)[Statements of Changes in Equity](#i3a6ad077e790432eb138c2b6742d6db7_34) | | | [59](#i3a6ad077e790432eb138c2b6742d6db7_34) | | |

| | | | [Consolidated](#i3a6ad077e790432eb138c2b6742d6db7_37) [Statements of Cash Flows](#i3a6ad077e790432eb138c2b6742d6db7_37) | | | [60](#i3a6ad077e790432eb138c2b6742d6db7_37) | | |

| | | | [Notes to the Consolidated](#i3a6ad077e790432eb138c2b6742d6db7_40) [Financial Statements](#i3a6ad077e790432eb138c2b6742d6db7_40) | | | [61](#i3a6ad077e790432eb138c2b6742d6db7_40) | | |

| | | | [Note 1.](#i3a6ad077e790432eb138c2b6742d6db7_40) [](#i3a6ad077e790432eb138c2b6742d6db7_40)[Organization and Basis of Presentation](#i3a6ad077e790432eb138c2b6742d6db7_40) | | | [61](#i3a6ad077e790432eb138c2b6742d6db7_40) | | |

| | | | [Note 2. Summary of Significant Accounting Policies](#i3a6ad077e790432eb138c2b6742d6db7_220) | | | [61](#i3a6ad077e790432eb138c2b6742d6db7_220) | | |

| | | | [Note 3. Revenue Recognition](#i3a6ad077e790432eb138c2b6742d6db7_43) | | | [70](#i3a6ad077e790432eb138c2b6742d6db7_43) | | |

| | | | [Note 4. Segment and Geographical Information](#i3a6ad077e790432eb138c2b6742d6db7_46) | | | [71](#i3a6ad077e790432eb138c2b6742d6db7_46) | | |

| | | | [Note 5. Receivables](#i3a6ad077e790432eb138c2b6742d6db7_49) | | | [73](#i3a6ad077e790432eb138c2b6742d6db7_49) | | |

| | | | [Note 6. Financing Receivables](#i3a6ad077e790432eb138c2b6742d6db7_52) | | | [74](#i3a6ad077e790432eb138c2b6742d6db7_52) | | |

| | | | [Note 7. Leases](#i3a6ad077e790432eb138c2b6742d6db7_232) | | | [74](#i3a6ad077e790432eb138c2b6742d6db7_232) | | |

| | | | [Note 8. Acquisitions, Goodwill, and Other Intangible Assets](#i3a6ad077e790432eb138c2b6742d6db7_58) | | | [75](#i3a6ad077e790432eb138c2b6742d6db7_58) | | |

| | | | [Note 9. Borrowings](#i3a6ad077e790432eb138c2b6742d6db7_61) | | | [78](#i3a6ad077e790432eb138c2b6742d6db7_61) | | |

| | | | [Note 10. Postretirement Benefit Plans](#i3a6ad077e790432eb138c2b6742d6db7_241) | | | [80](#i3a6ad077e790432eb138c2b6742d6db7_241) | | |

| | | | [Note 11. Income Taxes](#i3a6ad077e790432eb138c2b6742d6db7_244) | | | [85](#i3a6ad077e790432eb138c2b6742d6db7_244) | | |

| | | | [Note 12. Shareholders’ Equity](#i3a6ad077e790432eb138c2b6742d6db7_247) | | | [89](#i3a6ad077e790432eb138c2b6742d6db7_247) | | |

| | | | [Note 13. Financial Instruments and Fair Value Measurements](#i3a6ad077e790432eb138c2b6742d6db7_73) | | | [90](#i3a6ad077e790432eb138c2b6742d6db7_73) | | |

| | | | [Note 14. Commitments, Guarantees, Product Warranties, and Other Loss Contingencies](#i3a6ad077e790432eb138c2b6742d6db7_76) | | | [94](#i3a6ad077e790432eb138c2b6742d6db7_76) | | |

| | | | [Note 15. Restructuring Activities](#i3a6ad077e790432eb138c2b6742d6db7_79) | | | [95](#i3a6ad077e790432eb138c2b6742d6db7_79) | | |

| | | | [Note 16. Share-Based Compensation](#i3a6ad077e790432eb138c2b6742d6db7_256) | | | [96](#i3a6ad077e790432eb138c2b6742d6db7_256) | | |

| | | | [Note 17. Earnings Per Share](#i3a6ad077e790432eb138c2b6742d6db7_82) | | | [98](#i3a6ad077e790432eb138c2b6742d6db7_82) | | |

| | | | [Note 18. Supplemental Financial Information](#i3a6ad077e790432eb138c2b6742d6db7_85) | | | [98](#i3a6ad077e790432eb138c2b6742d6db7_85) | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | [Note 19. Related Parties and Transition Services Agreement](#i3a6ad077e790432eb138c2b6742d6db7_316) | | | [102](#i3a6ad077e790432eb138c2b6742d6db7_316) | | |

| | | | [Note 20. Subsequent Events](#i3a6ad077e790432eb138c2b6742d6db7_88) | | | [102](#i3a6ad077e790432eb138c2b6742d6db7_88) | | |

| | | | | | | | | |

| [Item 1.](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | | [Business](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | | [4](#ic5f48a2b80264b159361fdd8ef5e37cf_169) | | |

| [Item 2.](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | | [Properties](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | | [36](#ic5f48a2b80264b159361fdd8ef5e37cf_181) | | |

| [Item 6.](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | | [\[Reserved\]](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | | [37](#ic5f48a2b80264b159361fdd8ef5e37cf_187) | | |

| [Signatures](#ic5f48a2b80264b159361fdd8ef5e37cf_292) | | | | | | [112](#ic5f48a2b80264b159361fdd8ef5e37cf_292) | | |

- Risk identification begins with understanding the devices and equipment in use across the company, including [removed: laptops] [added: laptops, servers,] and other data devices, industrial equipment and machinery, and associated risks related to the use of those devices and equipment.

This team publishes information technology and security policies, measures compliance, [added: trains the workforce on cyber risks] and [added: protections, and] operates a program to [added: identify and] mitigate risks and threats.

Our risk mitigation activities include [added: workforce awareness, vulnerability management,] network segmentation, cyber protection and containment, [removed: detection and reaction,] [added: detection, response] and recovery.

To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company, including its business strategy, [removed: results of operations,] or financial [removed: condition.][added: results.]

[added: We describe whether and how cybersecurity-related risks could materially affect our business in Item 1A,] “Risk Factors” under the heading *“Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted [removed: cyber crimes] [added: cybercrimes] pose a risk to our systems, networks, products, solutions, services, and data, as well as our reputation, which could adversely affect our business.”*

The Audit Committee received reports from our Chief Information Officer (“CIO”) and/or CISO [removed: five] [added: four] times in [removed: 2024.][added: 2025.]

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

We describe whether and how cybersecurity-related risks could materially affect our business in item 1A.

GE HealthCare is a global organization [added: headquartered in Chicago, Illinois] with [added: other] major centers in or near [removed: Chicago,] [added: the following cities:] Milwaukee, Paris, Bangalore, and [removed: Shanghai, and is headquartered in Chicago, Illinois.][added: Shanghai.]

We have [removed: 43] [added: 44] manufacturing facilities, of which [removed: 30] [added: 32] are owned.

We have [removed: 15] [added: 14] manufacturing facilities located in the United States and [removed: 28] [added: 30] located outside of the United States, including in China, [added: Japan, Mexico, Norway,] India, Israel, [removed: Mexico,] [added: Germany,] Brazil, Austria, Denmark, France, [removed: Germany,] Ireland, the Netherlands, [removed: Norway,] Sweden, Finland, [removed: South Korea,] and [removed: Japan.][added: South Korea.]

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

There were [removed: 189,289] [added: 180,363] stockholders of record of GE HealthCare common stock as of [removed: February 6, 2025.][added: January 28, 2026.]

We declared [removed: and paid] a quarterly dividend of [removed: $0.03] [added: $0.035] per share to our stockholders of record for [removed: the first, second, and third quarter] [added: all quarters] of [removed: 2024.][added: 2025.]

The following graph compares the total return on the Company’s common stock for the last [removed: 24] [added: 36] months with the Standard & Poor’s 500 (“S&P 500”) and S&P 500 Healthcare indices.

The graph assumes $100 was invested in each of these indices on [added: January 4, 2023,] the first day of “regular way” trading for our common stock, and that all dividends were reinvested.

[removed: ][added: ]

ISSUER PURCHASES OF EQUITY SECURITIES.

On April 30, 2025, our Board of Directors authorized a share repurchase program (the “repurchase program”) pursuant to which GE HealthCare may repurchase up to $1,000 million of its common stock.

The repurchase program does not have an expiration date.

We did not repurchase any of our common stock during the three months ended December 31, 2025 and had $800 million available under the authorization as of December 31, 2025.

A “when issued” trading market for GE HealthCare’s common stock began on Nasdaq on December 16, 2022, and “regular way” trading of GE HealthCare’s common stock began on January 4, 2023.

Prior to December 16, 2022 there was no public market for GE HealthCare’s common stock.

In the fourth quarter of 2024, we declared a dividend of $0.035 per share to be paid in the first quarter of 2025.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| [removed: [Consolidated and Combined] [added: Consolidated] Statements of [removed: Income](#ic5f48a2b80264b159361fdd8ef5e37cf_28)] [added: Income] | | | [removed: [60](#ic5f48a2b80264b159361fdd8ef5e37cf_28)] | | | [added: | | | | | | | | | | | | | | |]

| [removed: [Consolidated and Combined] [added: Consolidated] Statements of Comprehensive Income [removed: (Loss)](#ic5f48a2b80264b159361fdd8ef5e37cf_31)] [added: (Loss)] | | | [removed: [61](#ic5f48a2b80264b159361fdd8ef5e37cf_31)] | | | [added: | | | | | | | | | | | | | | |]

[removed: | [Consolidated](#ic5f48a2b80264b159361fdd8ef5e37cf_34) [Statements of Financial Position](#ic5f48a2b80264b159361fdd8ef5e37cf_34) | | | [62](#ic5f48a2b80264b159361fdd8ef5e37cf_34) | | |][added: NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS]

| [removed: [Consolidated and Combined] [added: Consolidated] Statements of Changes in [removed: Equity](#ic5f48a2b80264b159361fdd8ef5e37cf_37)] [added: Equity] | | | [removed: [63](#ic5f48a2b80264b159361fdd8ef5e37cf_37)] | | | [added: | | | | | | | | | | | | | | | | | | | | | | | | | | |]

| [removed: [Consolidated](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [a](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[n](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[d](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[Combined](#ic5f48a2b80264b159361fdd8ef5e37cf_40) [](#ic5f48a2b80264b159361fdd8ef5e37cf_40)[Statements] [added: Consolidated Statements] of Cash [removed: Flows](#ic5f48a2b80264b159361fdd8ef5e37cf_40)] [added: Flows] | | | [removed: [64](#ic5f48a2b80264b159361fdd8ef5e37cf_40)] | | | [added: | | | | | |]

| [removed: [Note 6.] Financing [removed: Receivables](#ic5f48a2b80264b159361fdd8ef5e37cf_55)] [added: receivables – net] | | | [removed: [80](#ic5f48a2b80264b159361fdd8ef5e37cf_55)] [added: 95] | | | [added: 90 | | |]

[removed: | [Note 8. Acquisitions,] [added: Refer to Note 8, “Acquisitions,] Goodwill, and Other Intangible [removed: Assets](#ic5f48a2b80264b159361fdd8ef5e37cf_61) | | | [81](#ic5f48a2b80264b159361fdd8ef5e37cf_61) | | |][added: Assets” for further information.]

| [removed: [Note 12.] Accumulated [removed: Other Comprehensive (Income) Loss] [added: other comprehensive income (loss)] – [removed: Net](#ic5f48a2b80264b159361fdd8ef5e37cf_232)] [added: net] | | | [removed: [93](#ic5f48a2b80264b159361fdd8ef5e37cf_232)] [added: (1,388)] | | | [added: (1,379) | | |]

[removed: | [Note 13. Financial] [added: Refer to Note 13, “Financial] Instruments and Fair Value [removed: Measurements](#ic5f48a2b80264b159361fdd8ef5e37cf_76) | | | [94](#ic5f48a2b80264b159361fdd8ef5e37cf_76) | | |][added: Measurements” for further information.]

[removed: | [Note 14. Commitments,] [added: See Note 14, “Commitments,] Guarantees, Product Warranties, and Other Loss [removed: Contingencies](#ic5f48a2b80264b159361fdd8ef5e37cf_79) | | | [98](#ic5f48a2b80264b159361fdd8ef5e37cf_79) | | |][added: Contingencies” for further information.]

To the stockholders and the Board of Directors of GE HealthCare [removed: Technologies,] [added: Technologies] Inc.

We have audited the accompanying consolidated statements of financial position of GE HealthCare [removed: Technologies,] [added: Technologies] Inc. (the "Company") as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] the related consolidated [removed: and combined] statements of income, comprehensive income (loss), changes in equity, and cash flows, for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] and the related notes (collectively referred to as the "financial statements").

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 13, 2025,] [added: 4, 2026,] expressed an unqualified opinion on the Company's internal control over financial reporting.

We have audited the internal control over financial reporting of GE HealthCare Technologies Inc. (the “Company”) as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, [removed: 2024,] [added: 2025,] of the Company and our report dated February [removed: 13, 2025,] [added: 4, 2026,] expressed an unqualified opinion on those financial statements.

| (In millions, except per share amounts) | | | | | | | | | | | | [removed: 2024] [added: 2025] | | | [removed: 2023] [added: 2024] | | | [removed: 2022] [added: 2023] | | |

| Sales of products | | | | | | | | | | | | $ | [removed: 13,075] [added: 13,661] | | $ | [removed: 13,127] [added: 13,075] | | $ | [removed: 12,044] [added: 13,127] | |

| Sales of services | | | | | | | | | | | | [removed: 6,597] [added: 6,964] | | | [removed: 6,425] [added: 6,597] | | | [removed: 6,297] [added: 6,425] | | |

| Total revenues | | | | | | | | | | | | [removed: 19,672] [added: 20,625] | | | [removed: 19,552] [added: 19,672] | | | [removed: 18,341] [added: 19,552] | | |

| Cost of products | | | | | | | | | | | | [removed: 8,271] [added: 8,942] | | | [removed: 8,465] [added: 8,271] | | | [removed: 7,975] [added: 8,465] | | |

| Cost of services | | | | | | | | | | | | [removed: 3,196] [added: 3,436] | | | [removed: 3,165] [added: 3,196] | | | [removed: 3,187] [added: 3,165] | | |

| Gross profit | | | | | | | | | | | | [removed: 8,205] [added: 8,248] | | | [removed: 7,922] [added: 8,205] | | | [removed: 7,179] [added: 7,922] | | |

| Selling, general, and administrative | | | | | | | | | | | | [removed: 4,269] [added: 4,225] | | | [removed: 4,282] [added: 4,269] | | | [removed: 3,631] [added: 4,282] | | |

| Research and development | | | | | | | | | | | | [removed: 1,311] [added: 1,260] | | | [removed: 1,205] [added: 1,311] | | | [removed: 1,026] [added: 1,205] | | |

| Total operating expenses | | | | | | | | | | | | [removed: 5,580] [added: 5,485] | | | [removed: 5,487] [added: 5,580] | | | [removed: 4,657] [added: 5,487] | | |

| Operating income | | | | | | | | | | | | [removed: 2,625] [added: 2,763] | | | [removed: 2,435] [added: 2,625] | | | [removed: 2,522] [added: 2,435] | | |

| Interest and other financial charges – net | | | | | | | | | | | | [removed: 504] [added: 440] | | | [removed: 542] [added: 504] | | | [removed: 77] [added: 542] | | |

| Non-operating benefit (income) costs | | | | | | | | | | | | [removed: (406)] [added: (288)] | | | [removed: (382)] [added: (406)] | | | [removed: (5)] [added: (382)] | | |

| Other (income) expense – net | | | | | | | | | | | | [removed: (55)] [added: (157)] | | | [removed: (86)] [added: (55)] | | | [removed: (62)] [added: (86)] | | |

| Income from continuing operations before income taxes | | | | | | [removed: | | | | |] [added: $] | 2,581 | | [added: $] | 2,361 | | [removed: | 2,512 | | |]

| Benefit (provision) for income taxes | | | | | | | | | | | | [removed: (531)] [added: (614)] | | | [removed: (743)] [added: (531)] | | | [removed: (563)] [added: (743)] | | |

| Net income from continuing operations | | | | | | | | | | | | [removed: 2,050] [added: 2,154] | | | [removed: 1,618] [added: 2,050] | | | [removed: 1,949] [added: 1,618] | | |

| Income (loss) from discontinued operations, net of taxes | | | | | | | | | | | | — | | | [removed: (4)] [added: —] | | | [removed: 18] [added: (4)] | | |

| Net income | | | | | | | | | | | | [removed: 2,050] [added: 2,154] | | | [removed: 1,614] [added: 2,050] | | | [removed: 1,967] [added: 1,614] | | |

| Net (income) loss attributable to noncontrolling interests | | | | | | | | | | | | [removed: (57)] [added: (70)] | | | [removed: (46)] [added: (57)] | | | [removed: (51)] [added: (46)] | | |

| Net income attributable to GE HealthCare | | | | | | | | | | | | [removed: 1,993] [added: 2,084] | | | [removed: 1,568] [added: 1,993] | | | [removed: 1,916] [added: 1,568] | | |

| Deemed preferred stock dividend of redeemable noncontrolling interest | | | | | | | | | | | | — | | | [removed: (183)] [added: —] | | | [removed: —] [added: (183)] | | |

| Net income attributable to GE HealthCare common stockholders | | | | | | | | | | | | $ | [removed: 1,993] [added: 2,084] | | $ | [removed: 1,385] [added: 1,993] | | $ | [removed: 1,916] [added: 1,385] | |

Revenue Recognition – Allocation of the Transaction Price to Each Performance Obligation – Refer to Notes 2 and 3 to the financial statements

Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item, if reasonably available.

If such evidence is not reasonably available, the Company uses its best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors.

The Company’s allocation of the transaction price to each performance obligation involves judgments and estimates, including its best estimate of stand-alone selling price for performance obligations.

Auditing the Company’s allocation of the transaction price to the performance obligations in a contract required a high degree of auditor judgment and an increased extent of auditor effort.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Our audit procedures related to the allocation of the transaction price to the performance obligations included the following, among others:

- We tested the effectiveness of relevant controls related to the Company’s determination of stand-alone selling price and the allocation of transaction price to performance obligations.

- We selected certain products and services and tested the Company’s estimate of stand-alone selling price by evaluating historical prices charged for those performance obligations by the Company or other third parties, or by evaluating the reasonableness of the Company’s estimate if stand-alone selling prices were not available.

- We selected a sample of revenue transactions and tested the Company’s allocation of transaction price to performance obligations.

- We evaluated whether management’s revenue recognition accounting policies with respect to allocation of the transaction price to performance obligations are in accordance with Accounting Standards Codification 606, *Revenue from Contracts with Customers*, and evaluated the appropriateness of management’s application of those accounting policies in the determination of revenue recognition conclusions.

| February 4, 2026 | | |

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| February 4, 2026 | | |

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

The accompanying notes are an integral part of these consolidated financial statements.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| All other current assets | | | 726 | | | 532 | | |

| Accounts payable | | | 3,250 | | | 3,035 | | |

| Deferred income taxes | | | 193 | | | 56 | | |

The accompanying notes are an integral part of these consolidated financial statements.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| Issuance of shares under equity awards, net of shares withheld for taxes and other | | | 2 | | | — | | | — | | | — | | | (5) | | | — | | | — | | | — | | | — | | | (5) | | |

| Repurchase of common stock | | | — | | | — | | | 3 | | | (200) | | | — | | | — | | | — | | | — | | | — | | | (200) | | |

| Dividends declared ($0.14 per common share) | | | — | | | — | | | — | | | — | | | — | | | (64) | | | — | | | — | | | — | | | (64) | | |

| Balances as of December 31, 2025 | | | 459 | | | $ | 5 | | 3 | | | $ | (225) | | $ | 6,707 | | $ | 5,281 | | $ | — | | $ | (1,388) | | $ | 11 | | $ | 10,390 | |

The accompanying notes are an integral part of these consolidated financial statements.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| Net income | | | $ | 2,154 | | $ | 2,050 | | $ | 1,614 | |

| Gain on remeasurement of Nihon Medi-Physics equity method investment | | | (97) | | | — | | | — | | |

| Receivables | | | (216) | | | (157) | | | (173) | | |

| Repurchase of common stock | | | (200) | | | — | | | — | | |

The accompanying notes are an integral part of these consolidated financial statements.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

Following this transaction, GE continues to be considered a related party due to board member affiliation.

Refer to Note 19, “Related Parties and Transition Services Agreement” for further information.

Additionally, gain on fair value remeasurement of contingent consideration amounts, which was previously shown on a separate line on the Consolidated Statements of Cash Flows, was reclassified to All other operating activities – net.

We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances.

Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.

| | | | | | |

| Part II. Financial Information | | | | | |

| Index | | | | | |

| Item 8. Financial Statements and Supplementary Data | | | Page | | |

| [Report of Independent Registered Public Accounting Firm - Deloitte & Touche LLP (PCAOB ID No.](#ic5f48a2b80264b159361fdd8ef5e37cf_202) 34) | | | [57](#ic5f48a2b80264b159361fdd8ef5e37cf_202) | | |

| [Notes to the Consolidated and Combined Financial Statements](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | | [65](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | |

| [Note 1. Organization and Basis of Presentation](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | | [65](#ic5f48a2b80264b159361fdd8ef5e37cf_43) | | |

| [Note 2. Summary of Significant Accounting Policies](#ic5f48a2b80264b159361fdd8ef5e37cf_205) | | | [66](#ic5f48a2b80264b159361fdd8ef5e37cf_205) | | |

| [Note 3. Revenue Recognition](#ic5f48a2b80264b159361fdd8ef5e37cf_46) | | | [75](#ic5f48a2b80264b159361fdd8ef5e37cf_46) | | |

| [Note 4. Segment and Geographical Information](#ic5f48a2b80264b159361fdd8ef5e37cf_49) | | | [76](#ic5f48a2b80264b159361fdd8ef5e37cf_49) | | |

| [Note 5. Receivables](#ic5f48a2b80264b159361fdd8ef5e37cf_52) | | | [79](#ic5f48a2b80264b159361fdd8ef5e37cf_52) | | |

| [Note 7. Leases](#ic5f48a2b80264b159361fdd8ef5e37cf_58) | | | [80](#ic5f48a2b80264b159361fdd8ef5e37cf_58) | | |

| [Note 9. Borrowings](#ic5f48a2b80264b159361fdd8ef5e37cf_64) | | | [83](#ic5f48a2b80264b159361fdd8ef5e37cf_64) | | |

| [Note 10. Postretirement Benefit Plans](#ic5f48a2b80264b159361fdd8ef5e37cf_6597069768003) | | | [84](#ic5f48a2b80264b159361fdd8ef5e37cf_6597069768003) | | |

| [Note 11. Income Taxes](#ic5f48a2b80264b159361fdd8ef5e37cf_70) | | | [90](#ic5f48a2b80264b159361fdd8ef5e37cf_70) | | |

| [Note 15. Restructuring](#ic5f48a2b80264b159361fdd8ef5e37cf_82) [Activities](#ic5f48a2b80264b159361fdd8ef5e37cf_82) | | | [100](#ic5f48a2b80264b159361fdd8ef5e37cf_82) | | |

| [Note 16. Share-Based Compensation](#ic5f48a2b80264b159361fdd8ef5e37cf_244) | | | [100](#ic5f48a2b80264b159361fdd8ef5e37cf_244) | | |

| [Note 17. Earnings Per Share](#ic5f48a2b80264b159361fdd8ef5e37cf_85) | | | [102](#ic5f48a2b80264b159361fdd8ef5e37cf_85) | | |

| [Note 18. Supplemental Financial Information](#ic5f48a2b80264b159361fdd8ef5e37cf_88) | | | [103](#ic5f48a2b80264b159361fdd8ef5e37cf_88) | | |

| [Note 19. Related Parties](#ic5f48a2b80264b159361fdd8ef5e37cf_91) [and Tra](#ic5f48a2b80264b159361fdd8ef5e37cf_91)[nsition Services Agreement](#ic5f48a2b80264b159361fdd8ef5e37cf_91) | | | [106](#ic5f48a2b80264b159361fdd8ef5e37cf_91) | | |

| [Note 2](#ic5f48a2b80264b159361fdd8ef5e37cf_94)[0](#ic5f48a2b80264b159361fdd8ef5e37cf_94)[. Subsequent Events](#ic5f48a2b80264b159361fdd8ef5e37cf_94) | | | [108](#ic5f48a2b80264b159361fdd8ef5e37cf_94) | | |

Income Taxes – Valuation Allowance on Deferred Tax Assets — Refer to Notes 2 and 11 to the financial statements

The Company recognizes deferred income taxes for tax attributes and for differences between the financial statement and tax basis of assets and liabilities at enacted statutory tax rates in effect for the years in which the deferred tax liability or asset is expected to be settled or realized.

A valuation allowance is provided to offset deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Future realization of deferred tax assets depends on the existence of sufficient taxable income of the appropriate character.

Sources of taxable income include future reversals of deferred tax assets and liabilities, expected future taxable income, taxable income in prior carryback years if permitted under the tax law, and tax planning strategies.

The Company’s determination of the valuation allowance for certain deferred tax assets involves judgments and estimates, including the projected timing and pattern of future reversals of existing taxable temporary differences and the projection of future sources of taxable income.

Auditing management’s projected timing and pattern of future reversals of existing taxable temporary differences and the projection of future sources of taxable income, which affect the recorded valuation allowances for certain deferred tax assets, required a high degree of auditor judgment and an increased extent of effort, including the need to involve our income tax specialists.

With the assistance of our income tax specialists, our audit procedures related to the determination that it is more likely than not that sufficient taxable income will be generated in the future to realize certain net deferred tax assets included the following, among others:

- We considered relevant tax laws and regulations in evaluating the appropriateness of management’s estimates of future sources of taxable income.

- We evaluated the reasonableness of management’s estimates of future sources of taxable income by comparing the estimates to historical sources of taxable income or loss.

- We evaluated management’s projected timing and projected pattern of the reversals of existing taxable temporary differences.

- We evaluated whether the estimated future sources of taxable income were of the appropriate character to utilize the deferred tax assets under tax law.

| | | |

| February 13, 2025 | | |

| Consolidated and Combined Statements of Income | | | | | | | | | | | | | | | | | | | | |

| Consolidated and Combined Statements of Comprehensive Income (Loss) | | | | | | | | | | | | | | | | | | | | |

| Due from related parties | | | 5 | | | 32 | | |

| Due to related parties | | | 20 | | | 99 | | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2024,] [added: 2025,] and that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management has evaluated the effectiveness of the internal control over financial reporting, based on the framework and criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and concluded that they were effective as of December 31, [removed: 2024.][added: 2025.]

[removed: Other than those discussed in] [added: During] the [removed: preceding sentences,] [added: quarter ended December 31, 2025,] there were no changes in the Company’s internal control over financial reporting that [removed: occurred during the quarter ended December 31, 2024 that] materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

During the quarter ended December 31, 2024, the Company continued to exit from various transition service agreements with GE, primarily related to IT systems that impact financial reporting.

Consequently, responsibility for execution of related internal controls transferred to the Company, including general IT controls in connection with IT environment changes.

The information required under this item, with the exception of “Information About Our Executive Officers” and “Ethics and Governance” located under Item 1, “Business” of this Annual Report on Form 10-K, is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2024.][added: 2025.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2024.][added: 2025.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2024.][added: 2025.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2024.][added: 2025.]

The information required under this item is incorporated by reference to the Company’s definitive proxy statement pursuant to Regulation 14A, which will be filed with the Securities and Exchange Commission no later than 120 days after the close of the Company’s fiscal year ended December 31, [removed: 2024.][added: 2025.]

[Table of Contents](#i3a6ad077e790432eb138c2b6742d6db7_157)[](#i3a6ad077e790432eb138c2b6742d6db7_157)

| 4.1 | | | [Base Indenture, dated as of November 22, 2022, among GE HealthCare Holding LLC, General Electric Company, as guarantor, and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit [removed: 4.1](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) [to](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) [General] [added: 4.1 to General] Electric Company’s Current Report on Form 8-K filed with the SEC on November 23, 2022).](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex41.htm) | | |

| 4.2 | | | [First Supplemental Indenture, dated as of November 22, 2022, between GE HealthCare Holding LLC and The Bank of New York Mellon, as trustee (incorporated by reference to Exhibit [removed: 4.2](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) [to](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) [General] [added: 4.2 to General] Electric Company’s Current Report on Form 8-K filed with the SEC on November 23, 2022).](https://www.sec.gov/Archives/edgar/data/40545/000119312522292079/d425000dex42.htm) | | |

| 4.3 | | | [Second Supplemental [removed: Indenture](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[,] [added: Indenture,] dated as of August [removed: 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[4,](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [2024](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[, between](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [the] [added: 14, 2024, between the] Registrant [removed: and](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [T](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[he] [added: and The] Bank of [removed: New](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [York Me](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[llon,] [added: New York Mellon,] as [removed: trustee](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [(incorpo](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[rated] [added: trustee (incorporated] by [removed: reference](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [Exhibit 4.2](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [t](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[he Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm)[s] [added: reference to Exhibit 4.2 to the Registrant’s] Current Report on [removed: Form](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) [8-K] [added: Form 8-K] filed with the SEC on August 15, 2024).](https://www.sec.gov/Archives/edgar/data/1932393/000119312524201356/d868737dex42.htm) | | |

| [removed: 4.4] [added: 4.6] | | | [Description of Securities (incorporated by reference to Exhibit [removed: 4.4](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [t](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm)[o](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) [the] [added: 4.4 to the] Registrant’s Annual Report on Form 10-K filed with the SEC on February 15, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000025/ge4q202210kexhibit44.htm) | | |

| 10.2 | | | [removed: [Employee Matters] [added: [Trademark License] Agreement, dated [removed: January 2, 2023,] [added: December 31, 2022,] by and between General Electric Company and [removed: the Registrant] [added: GE HealthCare Imaging Holding Inc.] (incorporated by reference [removed: to] [added: into] Exhibit [removed: 10.3] [added: 10.4] to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex103.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex104.htm)†] | | |

| [removed: 10.3] [added: 10.24*] | | | [removed: [Trademark License Agreement, dated December 31, 2022, by and between General Electric Company and] [added: [2023] GE HealthCare [removed: Imaging Holding Inc.] [added: Performance Stock Unit Grant Agreement] (incorporated by reference [removed: into] [added: to] Exhibit [removed: 10.4] [added: 10.3] to the Registrant’s Current Report on Form 8-K filed with the SEC on [removed: January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex104.htm)†] [added: March 3, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000037/formofaward-2023ltippsugra.htm)] | | |

| [removed: 10.4] [added: 10.19*] | | | [removed: [Real Estate Matters Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant] [added: [One GE HealthCare Annual Bonus Plan] (incorporated by reference to Exhibit [removed: 10.5] [added: 10.4] to the Registrant’s Current Report on Form 8-K filed with the SEC on [removed: January 4, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556dex105.htm)] [added: February 3, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/onegehcannualbonusplaneffe.htm)] | | |

| [removed: 10.5] [added: 10.3] | | | [Form of Indemnification Agreement (incorporated by reference to Exhibit 10.7 to the Registrant’s Form 10 filed with the SEC on October 11, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522260650/d379971dex107.htm) | | |

| [removed: 10.6] [added: 10.4] | | | [removed: [Term Loan] [added: [Credit] Agreement, dated as [removed: of November 4, 2022,] [added: of](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [March 27, 2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[,] by and [removed: among GE HealthCare Holding LLC, as the borrower,] [added: among](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [the Registra](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[nt,](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [as] the [removed: lenders from time to time party thereto and Citibank,] [added: borrower,](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [JP](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[Morgan](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [Chase Bank,] N.A., as [removed: administrative agent (incorporated] [added: Administrative Agent](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[,](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [and](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [the lenders party thereto](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[(incorporated] by reference to Exhibit [removed: 10.8] [added: 10.1] to the Registrant’s [removed: Amendment No.1 to] Form [removed: 10] [added: 8-K] filed with the SEC [removed: on November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex108.htm)] [added: on](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm) [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit101.htm)] | | |

| [removed: 10.7] [added: 10.5] | | | [removed: [364-Day Revolving Credit] [added: [364-Day](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [Credit] Agreement, dated as [removed: of December 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[4](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[,] [added: of](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [March 27, 2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)[,] by and among [removed: GE HealthCare Technologies Inc.,] the [removed: lenders party thereto, and Citibank,] [added: Registrant, as the borrower,](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [JPMorgan Chase Bank,] N.A., as Administrative [removed: Agent](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)] [added: Agent](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)[, and](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [the lenders](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [party thereto](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)] [(incorporated by reference to Exhibit [removed: 10.1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm) [the Registrant’s Form 8-K filed] [added: 10.](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [to the](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [Current Report](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [on](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [Form 8-K](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [filed] with the SEC [removed: on December 1](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[4](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000119312524277089/d916467d8k.htm)] [added: on](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm) [March 31, 2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)[).](https://www.sec.gov/Archives/edgar/data/1932393/000193239325000007/exhibit102.htm)] | | |

| [removed: 10.8] [added: 10.18*] | | | [removed: [Credit Agreement, dated as of November 4, 2022, by and among the Registrant, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent] [added: [GE HealthCare Restoration Plan] (incorporated by reference to Exhibit [removed: 10.10] [added: 10.21] to the [removed: Registrant's] [added: Registrant’s] Amendment No. 1 to Form 10 filed with the SEC on November 7, [removed: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1010.htm)] [added: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1021.htm)] | | |

| [removed: 10.9*] [added: 10.7*] | | | [GE HealthCare 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.11](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) [the] [added: 10.11 to the] Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1011.htm) | | |

| [removed: 10.10*] [added: 10.8*] | | | [GE HealthCare Mirror 2022 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.12](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) [the] [added: 10.12 to the] Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1012.htm) | | |

| [removed: 10.11*] [added: 10.9*] | | | [GE HealthCare Mirror 2007 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.13](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) [the] [added: 10.13 to the] Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1013.htm) | | |

| [removed: 10.12*] [added: 10.10*] | | | [GE HealthCare Mirror 1990 Long-Term Incentive Plan (incorporated by reference to Exhibit [removed: 10.14](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) [to](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) [the] [added: 10.14 to the] Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522304909/d383836dex1014.htm) | | |

| [removed: 10.13*] [added: 10.11*] | | | [Offer Letter with Peter J. Arduini, dated June 15, 2021 (incorporated by reference to Exhibit 10.15 to the Registrant’s Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1015.htm) | | |

| [removed: 10.14*] [added: 10.12*] | | | [Amended Offer Letter with Peter J. Arduini, dated November 16, 2022 (incorporated by reference to Exhibit 10.16 to the Registrant’s Amendment No. 2 to Form 10 filed with the SEC on November 18, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522288985/d379971dex1016.htm) | | |

| [removed: 10.15*] [added: 10.13*] | | | [Offer Letter with Frank R. Jimenez, dated February 4, 2022 (incorporated by reference to Exhibit 10.13 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1013.htm) | | |

| [removed: 10.16*] [added: 10.14*] | | | [Offer Letter with James K. Saccaro, dated May 4, 2023 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on July 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit102.htm)† | | |

| [removed: 10.17*] [added: 10.15*] | | | [Offer Letter with Taha [removed: Kass-Hout,](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [dated September](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [9](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[, 202](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[2](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) [(incor](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[porate](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[d] [added: Kass-Hout, dated September 9, 2022 (incorporated] by reference to Exhibit 10.5 to the [removed: Registrant](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[’](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[s] [added: Registrant’s] Quarterly Report on Form [removed: 10-](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm)[Q] [added: 10-Q] filed with the SEC on April 30, 2024).](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000034/gehc1q202410qexhibit105.htm) | | |

| [removed: 10.18*] [added: 10.17*] | | | [removed: [Performance Stock Unit Grant Agreement for Peter J. Arduini, dated February 23, 2022] [added: [GE HealthCare Annual Executive Incentive Plan] (incorporated by reference to Exhibit [removed: 10.19] [added: 10.20] to the Registrant’s Amendment No. 1 to Form 10 filed with the SEC on November 7, [removed: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1019.htm)] [added: 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1020.htm)] | | |

| [removed: 10.19*] [added: 97.1] | | | [GE HealthCare [removed: Annual Executive Incentive Plan] [added: Technologies Inc. Clawback Policy] (incorporated by reference to Exhibit [removed: 10.20] [added: 97.1] to the Registrant’s [removed: Amendment No. 1 to] [added: Annual Report on] Form [removed: 10] [added: 10-K] filed with the SEC on [removed: November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1020.htm)] [added: February 6, 2024).](https://www.sec.gov/Archives/edgar/data/1932393/000193239324000013/ge4q202310kexhibit971.htm)] | | |

| [removed: 10.20*] [added: 10.21*] | | | [GE HealthCare [removed: Restoration] [added: Non-Employee Director Compensation and Benefits] Plan (incorporated by reference to Exhibit [removed: 10.21] [added: 10.9] to the Registrant’s [removed: Amendment No. 1 to] [added: Quarterly Report on] Form [removed: 10] [added: 10-Q] filed with the SEC on [removed: November 7, 2022).](https://www.sec.gov/Archives/edgar/data/1932393/000119312522279103/d379971dex1021.htm)] [added: April 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit109.htm)] | | |

| [removed: 10.21*] [added: 10.25*] | | | [removed: [One GE HealthCare Annual Bonus Plan] [added: [2023 Global Addendum] (incorporated by reference to Exhibit [removed: 10.4] [added: 10.3] to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/onegehcannualbonusplaneffe.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/formofawardgehealthcare-gl.htm)] | | |

| [removed: 10.22*] [added: 10.20*] | | | [GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on July 25, 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000112/gehc2q202310qexhibit101.htm) | | |

| [removed: 10.23*] [added: 10.35*] | | | [GE HealthCare [removed: Non-Employee] Director [removed: Compensation and Benefits Plan] [added: Restricted Stock Unit Grant Agreement] (incorporated by reference to Exhibit [removed: 10.9] [added: 10.10] to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit109.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000087/gehc1q202310qexhibit1010.htm)] | | |

| [removed: 10.24*] [added: 10.22*] | | | [removed: [GE] [added: [2023 GE] HealthCare [removed: Founders] Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on [removed: February] [added: March] 3, [removed: 2023)](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/formofaward2023ltiprsugran.htm).] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000037/formofaward-2023ltiprsugra.htm)] | | |

| [removed: 10.25*] [added: 10.23*] | | | [removed: [GE] [added: [2023 GE] HealthCare [removed: Founders] Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on [removed: February] [added: March] 3, [removed: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000012/formofaward2023ltipstockop.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1932393/000193239323000037/formofaward-2023ltipstocko.htm)] | | |